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ABSTRACT
Mechanisms of the Extreme Sensitivity of Turkeys to Aflatoxin B1

by

Sumit Rawal, Doctor of Philosophy
Utah State University, 2010

Major Professor: Dr. Roger A. Coulombe, Jr.
Department: Animal, Dairy and Veterinary Sciences

The pathogenesis of hepatotoxic and hepatocarcinogenic actions of the
mycotoxin aflatoxin B1 (AFB1) involves initial bioactivation by microsomal
cytochrome P450s (P450) to a reactive and electrophilic intermediate, exoaflatoxin B1-8,9-epoxide (exo-AFBO). Poultry, especially turkeys, are extremely
sensitive to AFB1, a condition associated with efficient epoxidation by P450s. The
purpose of this research was to 1) discover and characterize the P450s in turkey
liver responsible for AFB1 bioactivation, and 2) determine the relative importance
of these P450s in turkey liver.
Initial investigations led to the discovery of CYP1A5. We then identified
CYP3A37, a human CYP3A4 homologue from turkey liver, which along with
CYP1A5 plays an important role in the bioactivation of AFB1 to exo-AFBO. The E.
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coli-expressed CYP3A37 possessed striking similarities to human CYP3A4, in
terms of its catalytic activities and the kinetics of AFB1 oxidation.
After the discovery of CYP3A37, further research evaluated its relative
importance to CYP1A5, with respect to the epoxidation of AFB1, to determine
which of the homologues bioactivated relatively low “real world” AFB1
concentrations, reflective of the potential dietary exposure. Using antibodies
directed to both the enzymes as tools in immuno-inhibition experiments, we
determined that CYP1A5 contributes to about 98% of the exo-AFBO formation at
the low AFB1 concentrations (0.1 µM), which led us to conclude that CYP1A5 is
likely the dominant homologue involved in the extreme sensitivity of the turkeys
to AFB1. CYP3A37 also efficiently epoxidated AFB1, but only at high
concentrations of this mycotoxin, not likely to be achievable in turkey liver in
vivo. Our research has helped shed light on the relative importance of CYP1A5
and CYP3A37 in the bioactivation of AFB1 to the toxic exo-AFBO, and thus on the
mechanisms of the extreme sensitivity of turkeys to AFB1.
Given that AFB1 is a ubiquitous component of corn-based poultry feed
and contamination is practically unavoidable, we conducted further studies
evaluating the chemopreventive action of probiotic bacteria, Lactobacillus, on
AFB1 toxicity in turkeys. Probiotic bacteria are known to bind AFB1, thus
reducing its bioavailability. A mix of probiotic bacteria provided protection
against key endpoints of aflatoxicosis, like AFB1-induced reduction in body and
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liver weights. Our data demonstrate that Lactobacillus was protective against
aflatoxicosis in turkeys, thus validating its use as a possible chemopreventive,
thereby helping alleviate the significant annual losses to the poultry industry due
to feed contamination by AFB1.
(161 pages)
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CHAPTER 1
LITERATURE REVIEW1
Aflatoxins
Aflatoxins (AF) are the naturally occurring mycotoxins, produced as
secondary metabolites by the fungus Aspergillus flavus, A. parasiticus, and A.
nominus. The name “aflatoxin” is derived from the first letter in Aspergillus, and
the first three letters in flavus (Schoental, 1967). Structurally, AFs are
difurocoumarin derivatives that fluoresce under ultraviolet light. Depending
upon color of the fluorescence, AFs are divided into aflatoxin B1 and B2 (AFB1,
AFB2) for blue, and G1 and G2 (AFG1, AFG2) for green (Hartley et al., 1963; Dalvi,
1986) (Figure 1.1). Aflatoxin M1 and M2 (AFM1, AFM2), known as milk-AFs, are
the metabolites of AFB1 and AFB2, respectively (Carnaghan et al., 1963).
Aflatoxins are the most intensively researched group of mycotoxins, because of
their demonstrated toxic and carcinogenic effects in susceptible laboratory
animals and livestock and their acute toxicological and chronic
hepatocarcinogenic effects in humans. Of the known AFs, AFB1 is the most
potent, and is a classified human carcinogen (Wogan et al., 1974; Wong and
Hsieh, 1976; Bondy and Pestka, 2000).

Coauthored by Sumit Rawal, Ji Eun Kim and Roger A. Coulombe Jr. Portions of this review
have been submitted for publication to the Research in Veterinary Sciences.
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Toxicity of Aflatoxins
AFB1 is toxic to a wide range of animal species. AFB1 is principally an
hepatotoxin and hepatocarcinogen, but it causes a myriad of other effects either
directly or indirectly associated with this toxicity: immunosuppresion, reduced
growth rate, lowered milk and egg production, reduced reproductivity, reduced
feed utilization, reduced feed efficiency, and anemia. AFB1 has been shown to
induce hepatocellular carcinoma in many species of animals including fish
(rainbow trout, sockeye salmon, and guppy), poultry (turkeys, ducks, and geese),
non-human primates (rhesus, cynomolgus, African green, and squirrel
monkeys), and rodents (rats, mice, and tree shrews) (Wogan, 1992). A wide
variation exists in the dose of AFs required to produce signs of liver cancer in
different species. Fish and poultry, known to be extremely sensitive to AFB1,
responded to doses as low as 15-30 ppb. Rats responded at concentrations of 151000 ppb, whereas mice showed no effects to concentrations as high as 150, 000
ppb (Wogan, 1992). In rainbow trout, dietary AFB1 concentrations of 20 ppb
resulted in a liver tumor incidence of 62% (Bailey et al., 1988).
Primates showed a wide variability in AFB1 susceptibility to hepatic
tumors (Adamson, 1989). While squirrel monkeys developed liver cancer when
fed AFB1 at 2000 ppb for 13 months, much higher doses were required over a
longer period of time to induce low incidence of liver carcinoma in rhesus,
cynomolgus and African green monkeys (99 to 1,225 mg/animal administered
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p.o. over periods of 48 to 179 months). However, AFB1 induced tumors in
extraheptic tissues in the latter species.
Species susceptibility to various acute toxic manifestations, as measured
by TD50, is likewise variable (Gold et al., 1984; Wogan, 1992). While Fisher rats
appear to be extremely sensitive (TD50: 1.3 mg/kg/body weight/day), Swiss
mice are highly resistant (TD50: >5300 mg/kg/body weight/day). Rhesus and
cynomolgus monkeys dosed for an average of 3.3 and 14 years, respectively,
yielded a TD50 value of 156 and 848 mg/kg/body weight/day, respectively.
Acute aflatoxicosis in humans is manifested by vomiting, abdominal pain,
pulmonary edema, coma, convulsions, and death with cerebral edema and fatty
involvement of the liver, kidney, and heart (Strosnider et al., 2006). The
occurrence of acute aflatoxicosis was evidenced by the severe outbreak in Kenya
in 2004 (Probst et al., 2007). Epidemiological studies have consistently
demonstrated that AFB1 is a liver carcinogen in humans (Van Rensburg et al.,
1985; Groopman et al., 1988). Studies conducted in Swaziland and Guangxi,
China have linked AFB1 exposure to development of liver cancer in humans
(Peers et al., 1987; Yeh et al., 1989). The International Agency for Research on
Cancer has concluded that there is sufficient evidence for the carcinogenicity of
AFB1 in humans and hence placed this mycotoxin under group I (confirmed
carcinogen).
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Aflatoxin B1 is a “pro-carcinogen” in that enzymatic bioactivation is a
prerequisite for carcinogenic (and toxic) activity (Garner et al., 1972).
Accordingly, elucidation of the mechanisms of AFB1 metabolism has been the
focus of intense research over the years. AFB1 is metabolized by hepatic
microsomal cytochrome P450s (P450) to the reactive, electrophilic exo-AFB1-8,9epoxide (AFBO) which binds to DNA and other critical cellular macromolecules
(Ball and Coulombe, 1991; Wogan, 1992; Coulombe, 1993; Gallagher et al., 1996;
Guengerich et al., 1996a). The AFBO is highly unstable, and it reacts with DNA
to form N7 guanine adducts by intercalation of AFBO between base pairs (Iyer et
al., 1994).
In humans and most animals, the principal route of detoxification appears
to be through conjugation with endogenous glutathione (GSH), a reaction
catalyzed by glutathione-S-transferases (GSTs). There exists substantial amount
of evidence that the conjugation of the epoxide by GSH is a major factor in
determining the susceptibility of a species to AFB1 (Hayes et al., 1991). For
example, quail and rat are much more sensitive to AFB1 toxicity and
carcinogenicity than the more resistant mouse, yet all these animals exhibit high
rates of P450-mediated AFBO formation. The relatively high rate of GSH
conjugation by a constitutive alpha class GSTA3-3 appears to be the critical
resistance factor in mice (Hayes et al., 1992). Resistance in the rat to AFB1induced hepatocarcinogenesis can by enhanced by induction of a similar GST in
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liver which is constitutively expressed at low levels (Stresser et al., 1994). In nonhuman primates, evidence has been presented that GSTs in the mu-class, rather
than alpha, are most efficient in conjugation of AFBO (Wang et al., 2000). The
lack of a functional GST with affinity toward AFBO appears to be a major reason
that poultry are extremely susceptible to AFB1 (Klein et al., 2000).
There are a number of urinary and serum biomarkers that have been
validated to accurately predict AFB1 cancer risk in humans. Biomarkers for AF
exposure include dose-dependent urinary excretion of aflatoxin-N7-guanine and
AFM1 (Gan et al., 1988; Groopman et al., 1992; Groopman and Kensler, 1999).
Urinary excretion of mercapturic acid (AFB-NAC), a product of GSH adduction
of AFB1 mediated by GSTs, has also been used in field studies (Wang et al., 1999).
Serum AF-albumin adducts, which are positively associated with hepatocellular
carcinoma in humans (Wang et al., 1996) has found wide use in epidemiologic
studies (Wild and Turner, 2001). Analysis of serum adducts indicates a positive
correlation between dietary AFB1 exposure and serum AFB-albumin adducts
(Gan et al., 1988; Wild et al., 1992).
Aflatoxin B1 toxicity in Poultry
Poultry, especially turkeys, are extremely sensitive to the toxic effects of
AFB1 (Carnaghan et al., 1966; Arafa et al., 1981; Giambrone et al., 1985; Huff et al.,
1986; Kubena et al., 1995; Klein et al., 2000). Extreme sensitivity of turkeys to AFB1
was first and graphically demonstrated by association with „Turkey X Disease‟
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which caused widespread deaths of turkeys and other poultry throughout
Europe in the 1960s (Stevens et al., 1960). The disease was shown to be caused by
AFB1 contaminated feed (Smith, 1960). It was later reported that the
contamination with AFs came from Brazilian peanut meal (Blount, 1961). Among
different poultry species, turkeys were shown to be the most susceptible to AFs,
quail are intermediate, while chickens are considered relatively resistant (Arafa
et al., 1981; Lozano and Diaz, 2006). Although direct comparisons have not been
conducted, wild turkeys appear to be less susceptible to AFB1 than their
commercial counterparts (Quist et al., 2000).
Dietary aflatoxins at 0.7 ppm reduced the growth rate of turkey poults,
but had no effect in quails and chickens (Arafa et al., 1981). A diet containing 400
ppm AFB1 severely affected body and relative liver weights in turkeys, while
chickens showed no effect at this dietary concentration (Leeson et al., 1995). A
study examining the effects of AFB1 on the development of liver lesions in
poults, indicated ducks as more susceptible than turkeys and chickens (Coker,
1979). In that study, ducks developed hepatic lesions by dietary exposure to 30
ppb, turkeys at 300 ppb, while chickens responded to 500 ppb. Another study
evaluated the effects of AFB1 on the development of cytopathology in the
tracheal culture in day-old turkeys, Japanese quails, chicken and ducks (Colwell
et al., 1973). While cultures derived from ducks developed pathology at 6 ppb of
AFB1, the concentrations needed for equivalent pathology were as high as 100
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ppb for those from chickens. Tracheal cultures from turkeys and quails
responded to 28 and 47 ppb of AFB1, respectively.
Economic Losses to the Poultry Industry due to Aflatoxins
Turkeys are an important international food commodity. The United
States accounts for roughly one-half of the world‟s turkey production at
approximately 7.30 billion pounds, live weight, with an estimated value of nearly
US $ 3 billion (National Agricultural Statistics Service, USDA). The per capita
consumption of turkeys in the United States is approximately 18 pounds, and
turkeys are now the 4th major food and protein source, behind chicken, beef and
pork (National Turkey Federation).
Aflatoxins result in economic losses to the poultry industry from
reductions in growth rate, hatchability, feed efficiency and immunity towards
diseases (Richard et al., 1986; Coulombe, 1993). According to a report by the
Council for Agricultural Science and Technology, losses due to AFs to the US
poultry industry exceeded $143 million annually (CAST, 1989). A recent study
reported annual crop losses of $932 million due to mycotoxin contamination and
additional losses of $466 million in efforts to prevent or reduce contamination
(CAST, 2003). Although AFs are found in several feed ingredients, corn, peanut
meal, cottonseed meal, and sorghum appear to be at greatest risk for introducing
AFs in turkey diets (Pons and Goldblatt, 1965; Brekke et al., 1977; Winn and Lane,
1978; Hill et al., 1983). Crops contaminated with AFs are a worldwide problem
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and approximately 25% of world‟s food supply is contaminated with mycotoxins
(CAST, 1989). Conditions that favor contamination by mycotoxins include
excessive moisture both in field and post harvest storage, high humidity,
temperature extremes, drought stress and insect damage to crops (Coulombe,
1993). Aflatoxins are deleterious to poultry and their contamination in feed is
practically unavoidable (Coulombe et al., 2005). The United States Food and Drug
Administration regulates the amount of AFB1 allowed in poultry feed. The
current action level for corn and peanut products is 100 ppb and for cottonseed
meal 300 ppb.
Consumption of AFB1 contaminated feed results in poor performance,
decreased body and organ weights, immunosuppression, morbidity, and
mortality in turkeys (Kubena et al., 1990, 1991; Coulombe, 1993). Aflatoxins
significantly affect feed consumption, total plasmatic proteins and cholesterol
amounts of turkeys (Rauber et al., 2007). Furthermore, AFs lead to irreversible
liver damage as indicated by decreased liver-to-body weight ratios, liver enzyme
alterations, altered blood coagulation patterns, and histologic changes like
hepatocellular necrosis and biliary hyperplasia in turkeys (Quist et al., 2000; Klein
et al., 2002b). Dietary exposure of broiler hens to AF (10 ppm) resulted in
embryonic mortality and lowered the immunity in the progeny chicks (Qureshi
et al., 1998). Embryonic exposure with AFs resulted in long-term depression of
the immune function in chicks (Neldon-Ortiz and Qureshi, 1992). As in other
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species, the liver is the most severely affected organ in poultry, primary
consequences being hepatic necrosis and neoplasias (Klein et al., 2000).
AFB1 Metabolism in Poultry: Role of Cytochrome P450s
Cytochrome P450s are mixed-function oxidases that catalyze the
biotransformation of a wide variety of xenobiotics. They are a superfamily of
hemoproteins that aid in the oxidation of various substrates such as steroids,
eicosanoids, pharmaceuticals, pesticides, pollutants, and carcinogens (Parikh et
al., 1997). Cytochrome P450s play an important role in the formation of
carcinogenic and mutagenic electrophilic intermediates from naturally occurring
dietary compounds (Guengerich et al., 1996a). As mentioned previously, AFB1 is
not toxic per se, but requires metabolic conversion to the reactive and
electrophilic exo-AFBO by P450s to exert its toxic effects (Ball and Coulombe,
1991; Coulombe, 1993; Gallagher et al., 1996; Guengerich et al., 1996a). This
metabolite can induce mutations by alkylating DNA, principally at the N7
position of guanine forming the 8,9-dihydro-8-(N7-guanyl)-9-hydroxy-AFB1 (Lin
et al., 1977). In addition AFBO can bind to proteins and other critical cellular
nucleophiles.
Turkey liver P450s are especially efficient toward AFB1 bioactivation
compared to other poultry species thus far examined. Turkey liver microsomes
bioactivated AFs 1.8 and 3.5 times more than liver microsomes from quail and
chicken, respectively (Lozano and Diaz, 2006). When comparing livers obtained
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from 9, 45 and 61 day old turkeys, microsomes from younger were more active
toward AFB1 bioactivation than that from older birds (Klein et al., 2002a).
In turkey liver, AFB1 metabolism is mediated by homologues to human
CYP1A2 and CYP3A4 (Klein et al., 2000; Klein et al., 2003; Yip and Coulombe,
2006). Initial studies reported that concentrations of AFB1 which are likely to be
achieved in the liver following ingestion of “real-world” concentrations of AFB1
are bioactivated to AFBO primarily by CYP1A2, whereas much higher
concentrations are catalyzed by CYP3A4 (Gallagher et al., 1996; Kelly et al., 1997;
Van Vleet et al., 2002). CYP1A homologues also metabolize AFB1 to produce the
detoxified metabolite AFM1, whereas CYP3A enzymes produce another
detoxified metabolite, aflatoxin Q1 (AFQ1) (Campbell and Hayes, 1976;
Guengerich et al., 1996a) (Figure 1.2).
Although both CYP1A and 3A isoforms oxidize AFB1, there are conflicting
reports on their relative importance (Shimada and Guengerich, 1989; Ramsdell
and Eaton, 1990; Gallagher et al., 1994, 1996). A recent study demonstrated a
dominant contribution of CYP3A4 homologues in AFBO production. Aflatoxin
B1 metabolism studies in human liver microsomal preparations indicate a
predominant role for CYP3A4 and that its expression level was an important
determinant of the AFB1 disposition in human liver (Kamdem et al., 2006).
Specific CYP3A4 inhibitors like troleandomycin have been shown to inhibit
AFBO production (Gallagher et al., 1994), while inducers of CYP3A4 activity such
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as 3-methylcholanthrene and rifampicin, increase AFB1 metabolism in cultured
human hepatocytes (Langouet et al., 1995).
Although mammalian P450s are well described, limited information is
available on P450s in poultry, especially in the context of AFB1 metabolism.
Chicken P450s, CYP1A5 (Gilday et al., 1996) and CYP3A37 (Ourlin et al., 2000)
have been described. This laboratory recently cloned, expressed and
characterized CYP1A5 from turkey liver, the first functional protein amplified
from turkeys (Yip and Coulombe, 2006). CYP1A5 is predicted to be 528 amino
acids with 94.7% sequence identity to chicken CYP1A5. Like its human
homologue, the E. coli-expressed CYP1A5 efficiently bioactivated AFB1 to AFBO,
and in addition, produced AFM1. Recombinant P450 heterologously expressed in
E. coli proved to be very useful for the studies of turkey CYP1A5. After the
discovery of a CYP1A homologue, the next task was to identify the existence of
possible CYP3A4 homologue involved in AFB1 oxidation and determine its
relative importance compared to CYP1A5.
An important detoxification mechanism for AFB1 is the GST catalyzed
conjugation of AFBO with GSH (Hayes et al., 1991). Detoxification mediated by
GSTs plays a major role in species susceptibility to AFs (Coulombe, 1993).
Commercial turkeys appear to be deficient in this detoxification mechanism
which is an important reason for their extreme sensitivity to AFB1 (Klein et al.,
2000). Therefore, the extreme sensitivity of turkeys to AFB1, is, in part, due to a
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combination of efficient oxidation by P450s and deficient detoxification by GSTs
(Klein et al., 2000; Yip and Coulombe, 2006) (Figure 1.2).
Recombinant P450 systems to study
AFB1 Biotransformation
The study of P450s has been greatly facilitated by their expression in
heterologous systems, especially E. coli. The past two or three decades have seen
a tremendous growth in the engineering of recombinant P450s to study their
xenobiotic metabolism activity. Several expression hosts have been developed:
yeast (Murakami et al., 1987), mammalian cells (Crespi et al., 1991),
baculovirus/insect cells (Buters et al., 1994) and bacteria (E. coli). Escherichia coli
became a popular choice for the heterologous expression of P450s. The technique
started with the expression of P450 in E. coli through N-terminal modifications
(Barnes et al., 1991). Although this technique produced significant expression
levels for P450s (16 mg of spectrally detectable bovine P45017α per liter of
culture) (Barnes et al., 1991), the study of drug metabolism was often limited due
to the lack of endogenous electron donors NADPH-P450 reductase (NPR). While
E. coli contains flavoproteins which could couple to some degree with P450
(Jenkins and Waterman, 1994), the rate of catalysis was often slow. To overcome
this limitation P450s were co-expressed with NPR in E. coli (through bicistronic
expression or the use of fusion proteins) producing independent functionally
relevant P450 monooxygenase systems (Dong and Porter, 1996; Parikh et al.,
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1997). Thus, several P450s have been co-expressed with their partner reductase
successfully in E. coli (Parikh et al., 1997).
N-terminal modifications of native cDNAs: P450s were difficult to
express in their native form due to their hydrophobicity. Generally P450s require
alterations in the hydrophobic N-terminal nucleotide sequence (5‟ end) to
facilitate translation by E. coli (Barnes et al., 1991). This was due to the fact that Nterminal sequences serves as signal for membrane anchoring but plays no role in
the catalytic activity of P450 or its interactions with the coupling enzyme.
Initially, Barnes and coworkers (Barnes et al., 1991) were successful in the
expression of bovine P45017α1 by modifying N-terminal sequences. Specifically,
the second codon was changed to GCT (Ala) which encodes the LacZ gene, and
codons 4 and 5 were changed to increase the AT content by silent mutagenesis.
This reduced the free energy for base pairing and inhibited the formation of
secondary structures in the mRNA which could inhibit translation (Guengerich
et al., 1996a). This pioneering work led to abundant (16 mg of spectrally
detectable P450 per liter of culture) bovine P45017α1 expression levels in E. coli
(Barnes et al., 1991). Subsequently, several other P450s were expressed by
modifying and/or truncating the N-terminal sequences utilizing the above
mentioned strategy or using a different one (Fisher et al., 1992a, 1992b; Guo et al.,
1994; Sandhu et al., 1994). The majority of the methods for heterologously
expressed P450s follow a general procedure involving N-terminal sequence
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alterations. Native P450s usually were expressed in insignificant amounts
(Barnes et al., 1991; Dong and Porter, 1996). Another strategy of N-terminal
alteration is the fusion of a bacterial ompA (outer membrane protein A) leader
sequence (21 amino acids) and two additional spacer amino acids (Ala-Pro) to
P450 cDNAs in-frame with P450 initiation codon. This (Pritchard et al., 1997)
approach does not involve changes in the native P450 sequence and the leader
sequence is removed during bacterial synthesis releasing native P450.
Another 5‟ end modification is the introduction of a restriction site for
cloning in a vector {usually NdeI for cloning in pCW vector (Barnes et al., 1991)}.
Modifications at the 3‟ end usually involve introduction of 4-6 hisitidine residues
to facilitate purification of P450s by affinity Ni2+-NTA chromatography (Crowe et
al., 1994) and also to include a restriction site.
N-terminal modifications have been shown to not alter the catalytic
activities of the P450s, because of their prominent role in the membrane
localization (Barnes et al., 1991). These peptides do not participate in formation of
the active sites, which interact with the substrates. Loss of the catalytic activities
of the heterologously expressed P450s were mostly associated with the lack of
endogenous NPR and the necessary transfer of the electrons. Bicistronic vectors,
discussed below, overcame this difficulty by producing independent functionally
relevant P450s.
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Expression Vector: The pCW vector (Figure 1.3) developed in the
laboratory of Prof. F. W. Dahlquist has been used extensively to express modified
P450 cDNAs (Gegner and Dahlquist, 1991). pCW functions by two tac promoter
(inducible by isopropyl-thiogalactoisde:IPTG) cassettes upstream of an NdeI
(CATATG) restriction enzyme cloning site coincident with the initiation ATG
codon. This vector contains a strong transcription termination mechanism and a
phage M13 origin of DNA replication. Transcription prior to the addition of
inducing agents is inhibited by LacI gene encoding a lac repressor molecule.
pCW can also function as a bicistronic vector to co-express P450 and NADPHP450 reductase (Parikh et al., 1997). Bicistronic operons consisting of P450 cDNA
as the first cistron followed by NADPH-P450 reductase cDNA as the second
cistron can be ligated into the pCW vector multicloning site (Parikh et al., 1997).
The use of special restriction sites facilitates the process of subcloning in the
pCW vector. This bicistronic vector proved to be extremely useful for studying
the biotransformation of xenobiotics with P450s since it represented the fully
functional P450 monooxygenase system in whole cells or isolated membranes.
The presence of the reductase ensured that the electron transfer to P450 is not
rate- limiting as it was previously for just P450 expressed vectors. Dong and
Porter (1996) also produced a bicistronic vector pJL2E1/OR for expressing
P4502E1 with rat NPR. They employed a different technique which involved no
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modification of the N-terminal sequence. However, P450 yield was not
significant which limited the catalytic studies.
Another approach of producing a fully functional P450 monooxygenase
system comes with the co-expression of P450 with reductase as a fusion protein
(Fisher et al., 1992b; Shet et al., 1993) like the one present in naturally occurring
P450 BM3 (from Bacillus megaterium). The rationale for this approach is the
mutagenesis enabled alteration of C-terminal of P450 and N-terminal of
reductase to allow the fusion of the two sequences with a dipeptide linker, SerThr. These fusion proteins exhibited catalytic activity only in presence of
phospholipids and no apparent improvement in the activity was seen with their
use.
Because of its advantages mentioned above we chose bicistronic pCW
based vectors for expression in E. coli. Vectors other than pCW are also used for
P450 expressions, including pBSIISK (Stratagene), pSE420 (Invitrogen), pSE380
(Invitrogen), etc.
Expression in E. coli: Several strains of E. coli are commercially available:
such as JM109 (Invitrogen, Stratagene), XL 1-Blue (Stratagene), TOPP3
(Invitrogen, Stratagene), and DH5α (Invitrogen). Co-expression of P450 and
reductase in a bicistronic vector appears to be most efficient in DH5α (Parikh et
al., 1997; Yip and Coulombe, 2006). Expression constructs are transformed in
competent E. coli cells and streaked on Luria-Bertani (LB) agar/ampicillin plates,
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and allowed to grow at 37oC overnight. Starter culture consists of LB-ampicillin
medium inoculated with a single colony, and grown at 37oC with shaking.
Terrific broth (TB) medium has been extensively used for growing bacterial
cultures containing recombinant plasmids. It is usually supplemented with
thiamine, trace elements, ampicillin (50-100 μg/ml), heme precursor δaminolevulinic acid (δ- LA) (0.5 mM), and an inducer of transcription IPTG
(1mM). Cells are grown usually for 28-48 hr at 28-32oC. While some studies
indicate addition of IPTG at the start of TB culture (Guengerich et al., 1996b),
others have chosen to add IPTG after the cells in main culture in TB medium
have grown to an OD600 of 0.3-0.5 at 37oC (Jenkins et al., 1998; Yip and Coulombe,
2006). Addition of δ-ALA seems to increase P450 expression in some cases
(Gillam et al., 1995). Expressed P450s can be quantified in whole cells by CO
difference spectra, which is absorbance difference at 450 nm between reduced
hemoprotein (Fe2+) and the reduced hemoprotein bound to CO (Fe2+.CO)
(Omura and Sato, 1964).
Purification of P450 from membranes: Guengerich and coworkers
(Guengerich et al., 1996b), described a detailed method for the purification of
recombinant P450s expressed in E. coli. Bacterial cells in culture are harvested
and treated with lysozyme to prepare spheroplasts. Spheroplasts lysed in the
presence of protease inhibitors like phenylmethylsulfonyl fluoride (PMSF) gives
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rise to a lysate which is subjected to ultra centrifugation for 60 min at 4oC to
separate the membrane and cytosolic fraction.
Purification of P450 from the E. coli membranes makes use of the oligo-His
region at the C-terminal end Ni2+-NTA affinity chromatography (Crowe et al.,
1994). Membranes were first solubilized with surfactants/detergents like sodium
cholate, Triton X-114, CHAPS etc., before being subjected to chromatography (via
a combination of ion-exchange and affinity or just affinity) to purify enzyme
expressed in E. coli membranes (Hosea et al., 2000).
Chemoprevention of Aflatoxicosis in Poultry
The National Cancer Institute defines chemoprevention as the use of
naturally-occurring or synthetic agents to reduce the risk of, or delay the
development or recurrence of, cancer. Given that AFB1 contamination in the feed
is nearly universal, and therefore practically unavoidable (Coulombe et al., 2005),
chemoprevention strategies aimed at reducing AFB1 toxicity in poultry and in
other animals have been the subject of numerous studies (Klein et al., 2002b, 2003;
Guarisco et al., 2008a, 2008b). Several chemopreventives have been evaluated in
poultry for reducing symptoms of aflatoxicosis. Indeed, because of their
sensitivity, poultry have been used as models in the search for novel AFB1
chemopreventives.
Clay-based inorganic adsorbents, which prevent absorption of AFB1 into
the general circulation, hence reducing bioavailability, have been extensively
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studied. In broiler chicks, adsorbents like calcium montmorillonite clay (0.5, 0.25,
and 0.125% in diet), and Zeolites (1% in diet), which bind to AFB1 preventing
their absorption, have been shown to be protective against high AFB1 exposure
of 5 and 2.5 ppm, respectively (Miazzo et al., 2000; Pimpukdee et al., 2004).
Hydrated sodium calcium aluminosilicate (HSCAS), fed at dietary
concentrations ranging from 0.25-1%, has been shown to diminish the deleterious
effects of AF (up to 5 ppm in diet) in broiler chicks (Kubena et al., 1993, 1998;
Ledoux et al., 1999). Another adsorbent, clinoptilolite (15 g/kg), provided
moderate amelioration in AF associated liver toxicity (hydropic degeneration
and biliary hyperplasia) in broiler chicks (Ortatatli et al., 2005).
Detoxification of contaminated feed with microorganisms has been tested
as a strategy to reduce the AF-associated toxicity. In a recent study, the
detoxification potential of Nocardia corynebacteroides (NC), as a feed additive, was
evaluated in day-old Ross 308 chicks; NC significantly reduced the AF-associated
lesion severity in liver, duodenum and kidneys (Tejada-Castaneda et al., 2008).
Another report indicated the protective effect of Silymarin, a potent
hepatoprotective in humans, against aflatoxicosis in broiler chicks. Although the
mechanism of protection from Silymarin is uncertain, reports suggest that it acts
as an antioxidant and cell membrane stabilizer and promotes the cellular
synthesis of macromolecules (Tedesco et al., 2004). Dietary administration of a
Silymarin-phospholipid complex (600 mg/kg of body weight) resulted in

20
significant improvement in weight gain and feed intake in broiler chicks fed
AFB1 (0.8 ppm) in the diet (Tedesco et al., 2004). In addition, vitamin D and water
soluble vitamins like A, E and K are shown to be protective against aflatoxicosis
in quail chicks (Wilson et al., 1975, 1978).
The food antioxidant butylated hydroxytolouene (BHT) has been shown
in numerous studies to reduce symptoms of aflatoxicosis in mammalian and
avian models. In rodent models, BHT has been shown to reduce the development
of cancer by either induction of phase II enzymes like GSTs or inhibition of phase
I enzymes like P450s (Hocman, 1988; Singletary, 1990). Weight loss in chickens
due to AFB1 (3000 ppb in diet) was shown to be dramatically improved by
dietary BHT at a concentration of 0.39% (Larsen et al., 1985). Likewise, dietary
BHT protects against aflatoxicosis in turkeys. A diet containing 4000 ppm BHT
provided significant protection against AFB1-induced weight loss, hepatocellular
necrosis, biliary hyperplasia and changes in serum enzymes indicative of
hepatotoxicity, in turkeys (Klein et al., 2002b). Mechanism studies later revealed
that while BHT induced GST expression and activity, none of the GSTs so
induced had affinity toward AFBO (Klein et al., 2003). The protective properties
of BHT appeared to be due to an inhibitory effect on the activity of P450 1A1 and
1A2, suggesting reduced bioactivation of AFB1 to the AFBO (Klein et al., 2003).
Further studies revealed that dietary BHT reduced AFBO formation, as well as
other CYP1A5-mediated activities (Guarisco et al., 2008b). Importantly, BHT
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inhibited conversion of AFB1 to AFBO, exhibiting Michaelis-Menton competitive
inhibition kinetics (Ki=0.81 µM). Inhibition of AFBO formation was found in
microsomes prepared from the birds fed 4000 ppm BHT, as well as in
microsomes treated with BHT in vitro. Moreover, BHT (4000 ppm in the diet for
10 days) caused significant reductions in AFB1 bioavailability, AFB1–DNA
adduct formation in the liver, and AFB1 residues in tissues in turkeys (Guarisco
et al., 2008a).
A number of recent studies have demonstrated that probiotic bacteria
offers protection against AFB1 in humans and animals. The mechanism of
protection is through binding of AFB1 by cell wall constituents of probiotic
bacteria, such as Lactobacillus rhamnosus. Because of its use in various dairy
products including yogurt, L. rhamnosus is considered a safe and effective
chemopreventive. Lactobacillus rhamnosus strain GG and LC-705 were found to be
most efficient in binding a range of mycotoxins including AF (El-Nezami et al.,
1998, 2002a, 2002b; Haskard et al., 2001; Peltonen et al., 2001). In addition, L.
rhamnosus reduced AFB1 transport, metabolism, and toxicity in cultured Caco-2
cells (Gratz et al., 2007). Furthermore, L. rhamnosus reduced AFB1 bioavailability
in rats, thereby decreasing its toxicity (Gratz et al., 2006). Thus, there exists
substantial evidence of the protective role of probiotics in preventing
aflatoxicosis. Given the potential of probiotic bacteria in binding AFB1, the
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present study aims to evaluate their chemopreventive action on AFB1 toxicity in
turkeys, a species extremely susceptible to aflatoxicosis.
Research Goals
Given the importance of P450s in the metabolic activation of AFB1, leading
to its toxicity, the aim of this research was to discover and characterize the P450
homologues involved in the bioactivation of AFB1 in turkey liver and to
determine their relative importance. Given that AFB1 is nearly ubiquitous in
corn-based poultry feed and contamination is practically unavoidable, another
goal was to evaluate the chemopreventive action of o probiotic bacteria,
Lactobacillus, on AFB1 toxicity in turkeys.
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Figure 1.1. Chemical structures of major aflatoxins
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Figure 1.2. Metabolism of AFB1: role of P450s and GSTs. The extreme sensitivity
of turkeys to AFB1 is associated with efficient AFB1 epoxidation catalyzed by
CYP1A5 and CYP3A37 coupled with deficient GST detoxification. The
hydroxylated metabolites, AFM1 and AFQ1 are formed by CYP1A5 and
CYP3A37, respectively.
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Figure 1.3. A pCW based bicistronic vector for co-expression of P450 with human
NADPH P450 reductase (adapted from Gillam and Guengerich, 2001). The P450
and reducatse cDNAs are inserted in series in a single expression cassette under
the control of tandem tac promoters. Each cDNA is optimally positioned with a
ribosomal binding site. The operons are driven by IPTG inducible double tac
promoters placed upstream of first cistron.
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CHAPTER 2
STRUCTURE, GENETIC MAPPING, AND FUNCTION OF THE
CYTOCHROME P450 3A37 GENE IN THE TURKEY (MELEAGRIS
GALLOPAVO)2
Abstract
Cytochromes P450 (P450 for protein; CYP for gene) are a superfamily of
membrane-bound hemoproteins that oxidize a large number of endogenous and
exogenous compounds. Through oxidation reactions, these enzymes are often
responsible for the toxic and carcinogenic effects of natural food-borne toxicants,
such as the mycotoxin aflatoxin B1 (AFB1). Previous studies in our laboratory
have shown that the extreme sensitivity of turkeys to AFB1 is in part explained
by efficient hepatic P450-mediated epoxidation to the toxic and reactive
metabolite, exo-AFB1-8,9-epoxide (AFBO). Using 3‟-5‟-rapid amplification of
cDNA ends (RACE), we amplified CYP3A37 from turkey liver RNA, the E. coliexpressed protein which efficiently epoxidates AFB1. Turkey CYP3A37 has an
ORF of 1512 bp, and the protein is predicted to be 504 amino acids with 97%
homology to chicken CYP3A37. The turkey gene is organized into 13 exons and
12 introns. A single nucleotide polymorphism in the 11th intron was used to
assign CYP3A37 to turkey linkage group 10 (corresponding to chicken
Coauthored by Sumit Rawal, Kristelle M. Mendoza, Kent M. Reed, and Roger A. Coulombe Jr.
(2009) Cytogenetics and Genome Research 125: 67-73. © 2010 S. Karger AG, Basel. Reprinted with
permission.
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chromosome 14, GGA14). Because of the important role of P450s in the extreme
sensitivity of turkeys to the toxic effects of AFB1, this study will contribute to the
identifying allelic variants of this important gene in poultry.
Introduction
Cytochromes P450 (“P450” for protein; CYP for gene) are a superfamily of
hemoproteins that catalyze a large number of endogenous and exogenous
compounds. Of particular relevance to toxicology, P450s are known to oxidize
hundreds of environmental chemicals to form reactive intermediates that are
toxic and carcinogenic. One good example is the carcinogenic mycotoxin
aflatoxin B1 that requires P450 oxidation at the 8,9 vinyl bond to produce the
reactive and electrophilic exo-AFB1-8,9-epoxide (AFBO) to exert its toxic and
carcinogenic properties (Van Vleet et al., 2002). The critical lesion responsible for
these properties is the 8,9-dihydro-8-(N7-guanyl)-9-hydroxy-AFB1 adduct
formed when the AFBO reacts with DNA (Iyer et al., 1994). Much of the
observed interspecies variability in susceptibility to AFB1 can be attributed to
differences in AFB1 biotransformation (Eaton and Gallagher, 1994). Aflatoxin B1
is a recognized hepatocarcinogen and hepatotoxicant in humans and animals. In
humans, AFB1 is epoxidated principally by P4503A4 (the major P450 form in the
liver), and to a lesser extent by P4501A2 (Kamdem et al., 2006).
Turkeys are extremely sensitive to the toxic effects of AFB1 (Coulombe,
1993; Giambrone et al., 1985), a condition we have previously shown to be
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associated with efficient hepatic P450-mediated epoxidation. As in humans, AFB1
is epoxidated to AFBO by both P450 1A and 3A homologues in turkey liver
(Klein et al., 2000). Aflatoxin B1 was discovered in the early 1960s as the
etiological agent of “Turkey X” disease, responsible for the widespread deaths of
turkeys and other poultry throughout Europe due to contaminated Brazilian
peanut meal in feed (Asao et al., 1965). We recently cloned and expressed
P4501A5 from turkey liver, which like the human homologue, P4501A2,
efficiently epoxidates AFB1 to produce the exo-AFBO as well as the detoxified
metabolite aflatoxin M1 (Yip and Coulombe, 2006). Because of the importance of
P4503A4 in the toxicity of AFB1 in humans and animals, we sought to
characterize the homologue of this enzyme in turkey liver. Here, we report the
cloning, genetic mapping and biological activity of P4503A37 from turkey. Like
P4503A4, the human homologue, the expressed protein from CYP3A37
efficiently epoxidates AFB1 to form exo-AFBO.
Materials and Methods
Gene amplification, sequencing, and genetic mapping. Messenger
RNAs from one-day-old male turkeys were amplified by 3‟-5‟ RACE as described
(Yip and Coulombe, 2006). Primers used in 3‟-RACE were designed based on
ClustalW (www.ebi.ac.uk) sequence alignments of CYP3A4 in human and cattle,
3A4v2 in Cercopithecus aethiops (African green monkey), 3A44 in mouse, 3A66 in
Macaca mulatta (rhesus monkey) and 3A45 in Onchorhynchus mykiss (rainbow
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trout) . The gene-specific forward primer sequence for 3‟-RACE of turkey
CYP3A37 was 5‟-TTTGGAASTGGACCCAGRAACTGCATTGGC-3‟. The genespecific reverse primer for 5‟-RACE was 5‟GCAACTTTCAGAGTCAAGAGAGCAAATCGC-3‟. All reactions used a
mixture of two universal primers (long primer: 5‟CTAATACGACTCACTATAGGGCAAGCAGTGGTATCAACGCAGAGT-3‟ and
short primer: 5‟-CTAATACGACTCACTATAGGGC-3‟) provided in the BD
SMART RACE cDNA Amplification Kit (BD Biosciences Clontech, Palo Alto,
CA). The full-length turkey CYP3A37 gene was cloned using forward and
reverse primers designed from the sequence information obtained from 3‟- and
5‟-RACE (CYP3A37 full-length forward primer: 5‟
CTGGGACAGATGGACAGAGAC-3‟, reverse primer: 5‟GTACACCAAGAAGAAAGTCACCCATCTC-3‟).
To identify segregating markers to genetically map CYP3A37 in the turkey
genome the turkey mRNA (GenBank DQ450083) was aligned with the chicken
whole genome sequence. Based on this alignment, primers were designed to
amplify by PCR the intervening sequence between exons 11 and 12 of the
CYP3A37 gene. Primer sequences were as follows; exon11_forward 5‟CCCAGAGGAGTTCAGACCAG-3‟ and exon12_reverse 5‟CATCCCAATGCAGTTCCTG -3‟. This fragment was amplified and sequenced
from DNA pools representing the F1 generation of the UMN/NTBF mapping
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families (Reed et al., 2003). Each DNA pool included three individuals; one sire
and the two dams to which it had been crossed. Genotypes were then obtained
for informative families of the UMN/NTBF mapping population by digestion of
CYP3A37 intron 11 amplicons directly with restriction endonucleases followed
by electrophoresis in 1% agarose (PCR/RFLP). Two-point linkage analysis of the
genotypes for a SNP in intron 11 and markers already placed on the turkey
linkage map (Reed et al., 2007b) was performed using Locusmap (Garbe and Da,
2003).
Analysis of biological activity. Bicistronic expression constructs
consisting of the coding sequence of CYP3A37 (GenBank DQ450083) followed by
that of human NADPH-P450 reductase (hNPR), the redox partner to P450, were
constructed as described previously (Yip and Coulombe, 2006). Two variants of
CYP3A37 were cloned: the wild-type sequence (wtCYP3A37) and an N-terminal
truncated sequence (tCYP3A37). Deletion of hydrophobic N-terminal amino
acids and other modifications have previously shown to increase the expression
level of P450s in E. coli (Shimada et al., 1997), so we engineered the truncated
sequence (tCYP3A37) by deleting 11 codons in this region. In addition, the
nucleotide sequences of first eight codons were modified to enhance protein
expression (Barnes et al., 1991). A 6X His tag was also added to facilitate
immunodetection and purification. The expression constructs were created by
digesting the original pCW1A2/hNPR vector with NdeI and XbaI to excise the
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CYP1A2 coding sequence. The gel-purified vector fragment was ligated with the
wild-type or truncated CYP3A37 NdeI- and XbaI-digested, PCR-amplified
fragment using T4 DNA ligase. The resulting ligation mix was transformed into
DH5αF‟IQ cells. Individual clones were screened by colony PCR and diagnostic
restriction digestion before being sequenced. Sequences in the entire reading
frame of both constructs as well as the 5‟- and 3‟-junctions of the inserts to the
vectors were verified before individual clones were used in expression. The final
expression plasmids were transformed into DH5αF‟IQ cells.
Heterologous expression of tCYP3A37 in E. coli (Jenkins et al., 1998) was
carried out by inoculating 5 ml of Luria-Bertani ampicillin medium with a single
colony of DH5αF‟IQ E. coli transformants, which was then incubated for 23 hr
with shaking (150 rpm) at 30 C. Levels of P450 expression were determined by
reduced CO/reduced difference spectrum (Genesys 6 UV-vis spectrophotometer,
Thermo Spectronic, Rochester, NY). E. coli membranes and cytosol were then
prepared for AFB1 metabolism experiments (Yip and Coulombe, 2006).
The oxidation activity toward AFB1 was determined by HPLC using
conditions that we have described previously (Yip and Coulombe, 2006), which
were optimized in preliminary experiments. Because of its short half-life, AFBO
was indirectly measured as the glutathione (GSH)-trapped conjugate, which
provides an accurate and quantitative measurement (Ramsdell and Eaton, 1990).
E. coli membranes expressing tP4503A37 (0.307 μM), BHA-induced mouse
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cytosol (~ 800 μg) as a source of glutathione S-transferase (GST), and 2-250 μM
AFB1 was added to the assay mixture as substrate. The reactions were incubated
at 37 C for 20 min with gentle shaking and stopped by 250 μl of cold MeOH
spiked with 24 μM aflatoxin G1 (AFG1) as an internal standard. Metabolite
formation was calculated by establishing calibration curves between the peak
areas in the chromatograms and the amounts of metabolites injected, using
authentic AFBO-GSH HPLC standards. Kinetic data were analyzed by
SigmaPlot Enzyme Kinetics Module software (Systat, San Jose, CA) and were fit
using the Michaelis-Menten equation V = Vmax [S]/([S] + Km) and nonlinear
regression analysis to calculate the kinetic constants Vmax and Km.
Results
Sequence and structure of CYP3A37. Sequence analysis of clones that
covered the entire reading frame of CYP3A37 revealed a sequence of 1512 bp
coding for 504 amino acids (Figure 2.1). Like the human homologue, the turkey
CYP3A37 gene is organized into 13 exons and 12 introns. The 13 exons of the
turkey gene were 124, 94, 53, 100, 114, 89, 149 128, 73, 161, 227, 161 and 477 bases
in length. Exons 1 and 13 contain 71 and 93 coding nucleotides, respectively.
Our previous examination of CYP1A5 (Reed et al., 2007a) found identical gene
structure between the turkey and chicken homologues. Alignment of the turkey
CYP3A37 mRNA with the chicken whole genome sequence (release 2.1) indicates
introns of 2561, 312, 1080, 477, 255, 718, 447, 691, 162, 429, 454, and 120 bases in
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length (Figure 2.2). Alignment of the turkey mRNA sequence with that of the
chicken (NM_001001751, Figure 2.3) indicated 94.2% nucleic acid sequence
similarity. Most notably, the turkey CYP3A37 gene was found to be 4 amino
acids shorter than the chicken homologue due to a 12 bp insertion/deletion in
exon 9 (Figure 2.1). In addition to this length difference, 36 amino acid
substitutions are predicted between chicken and turkey, with 92.8% similarity.
Genetic mapping of CYP3A37. Intron-containing fragments totaling 560
bp were sequenced from the turkey DNA pools (Genbank EU216548). Sequence
similarity of CYP3A37 intron 11 between the turkey and chicken was 92.4%. A
single G > A SNP at position 256 of the 454 bp intron was identified in the F1
individuals of the UMN/NTBF mapping population. This polymorphism
occurred within the recognition sequence of the restriction endonuclease Bsl I (5'CCNNNNN▼NNGG-3‟) and this enzyme was used for PCR/RFLP genotyping
of the mapping families. Genotypes at the CYP3A37 SNP (256G>A) were
combined with the markers in the current UMN database (Reed et al., 2007b).
Linkage analysis of the SNP genotypes (83 informative meioses) revealed
significant linkage (two-point LOD score >3.0) between the CYP3A37 SNP and a
microsatellite marker in turkey linkage group M10 (corresponding to chicken
chromosome 14, GGA14). Distance between CYP3A37 and MNT323 was 9.9 cM
(LOD 13.04, Figure 2.3).
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Activity of E. coli-expressed CYP3A37. Because of their strong
hydrophobicity in the N-terminal region, wild-type eukaryotic P450s without Nterminal modifications are often not expressed in E. coli (Guo et al., 1994), and
wtCYP3A37 was no exception to this observation. Our approach of producing
the truncated tCYP3A37 resulted in a relatively high level of protein expression,
with 300-400 nmol tCYP3A37 per liter of culture, as estimated by the reduced
CO/reduced difference spectrum of whole cells. After membrane and cytosol
isolation, approximately 27% of the tCYP3A37 was recovered in the membrane
fraction, and 20-40% was in the cytosol fraction. Membranes from E. coliexpressing tCYP3A37 also expressed active hNPR, the redox partner necessary
for P450-mediated catalysis. The activity of hNPR, measured by reduction of
cytochrome c, was 0.42 µmol/min/mg total protein.
The P4503A37-expressing E. coli membranes efficiently epoxidated AFB1
to the exo-AFBO in our HPLC-based in vitro assay. Formation of this active
metabolite conformed to Michaelis-Menten kinetics (Figure 2.4). The Km and Vmax
values of exo-AFB1 formation were 21.6 + 6.4 μM and 1.3 + 0.1 nmol/min/nmol
P450, respectively (R2 = 0.746).
Discussion
Biotransformation to AFBO is the necessary first step in the development
of toxic and carcinogenic activity of AFB1 in animals, and P450s are the most
important enzymes in this process (Coulombe, 1993). The adverse effects of
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AFBO is due to its reactivity toward DNA and other critical cellular
macromolecules (Guengerich, 2008). In turkeys, as in humans and other animals,
AFB1 is bioactivated mainly by P4501A2 and 3A4 homologues (Klein et al., 2000).
In humans, P4503A4 is the predominant form which epoxidates AFB1 at
environmentally-relevant substrate concentrations (Kamdem et al., 2006). Thus,
the discovery of the CYP3A4 homologue CYP3A37 in turkey liver is of
substantial importance in discerning the mechanisms of the extreme sensitivity
of this species to AFB1.
The structure of CYP3A37 in turkey is markedly similar to that of chicken
CYP3A37 and the human homologue CYP3A4 with thirteen exons and twelve
introns. All 13 exons are, at least in part, translated. With the exception of exons
9 and 13, the number of amino acid residues encoded in aligned transcripts is
conserved among the two poultry species and human. Turkey exon 13 was one
residue longer in humans. The most notable differences occurred in exon 9 in
which the turkey exon is 12 bp (4 aa) shorter than the corresponding chicken
sequence. Interestingly, exon 9 in humans (NM_017460) is similar to that of
turkey in that it is 18 bp shorter in the same region as the chicken protein. This
region, which lies between two helix domains (human resides 271-279 and 292323) may be less functionally constrained. Two alternate-spliced transcripts (503
and 353 residues) are reported for human CYP3A4. Splice variants were not
observed in the turkey. A search of the NCBI EST database identified 19
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CYP3A37 transcripts for the chicken, none of which indicated splice variants
upon alignment.
Linkage of CYP3A37 to markers in turkey linkage group M10 is consistent
with the position of CYP3A37 in the chicken whole genome sequence,
approximately 0.9 Mbp from MNT323. In humans, CYP3A4 is found in a cluster
with other P450 genes on HGA7q21.1. In the chicken (and turkey, data not
shown), a second P450 gene CYP3A80 is found adjacent to CYP3A37.
Investigations of this P450 gene are ongoing in our laboratory.
Membranes from E. coli-expressing CYP3A37 efficiently converted AFB1 to
AFBO. This confirms our previous observation of the presence of a CYP3A4
homologue in turkey liver microsomes (Klein et al., 2000). The kinetic constants
for exo-AFB formation by tP4503A37 compared to that reported for tP4501A5
(Yip and Coulombe, 2006) indicate that the former has a higher AFB1 epoxidation
activity (Km = 21.6 + 6.4 vs. 65 + 12 μM; Vmax = 1.3 + 0.1 vs. 0.61 + 0.04
nmol/min/nmol P450). Based simply on these kinetic constants, it is safe to
assume that CYP3A37 plays an important role in AFB1 bioactivation in turkey
liver in vivo. However, a confirmation of the relative roles of CYP3A37 and
CYP1A5 in turkey liver microsomses awaits immunoinhibiton studies which are
currently underway in this laboratory. By comparison, lymphoblastoid
microsomes expressing human CYP3A4 cDNA exhibited slightly different kinetic
constants than CYP3A37 (Km = 133 μM; Vmax = 6.2 nmol/min/nmol P450)
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(Gallagher et al., 1994). Such interspecies rate differences are to be expected, but
may also be explained by the different expression systems.
Due to extreme susceptibility of poultry, especially turkeys, to the toxic
and carcinogenic effects of AFB1, development of molecular markers (SNPs
and/or microsatellites) in genes coding for critical genes like CYP3A37 will be
important in tracking susceptibility traits. Because of the striking similarities
between the sequences of turkey and chicken, this work can be of benefit to the
entire poultry industry.
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Figure 2.1. Aligned coding regions of turkey (GenBank DQ450083) and chicken
(GenBank NM_001001751) CYP3A37 cDNAs. Predicted amino acid sequences
for each gene are given below the nucleotide sequence. Exon junctions based on
alignments with genomic DNA are indicated above the chicken sequence.
Position (underlined) of PCR primers used in genotyping are indicated. A 12 bp
deletion in the turkey exon 9 is shown as dashes.
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Figure 2.2. Idiogram of turkey CYP3A37 indicating position of exons and introns
as determined by alignment of the turkey mRNA sequence (DQ450083) to the
chicken whole genome sequence. Location of the 256G>A SNP used for linkage
mapping is indicated by the arrow. Length of exons (above) and introns (below)
are presented, coding nucleotides included in exons 1 and 13 are indicated in
parentheses.
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Figure 2.3. Physical map of chicken chromosome 14 (GGA14) based on positions
(determined by BLASTN) of genetically mapped turkey sequences (Reed et al.,
2007b) aligned with assembly 2.1 of the chicken whole-genome sequence (units =
bp).
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Figure 2.4. Michaelis-Menten plot for AFB1 oxidation by E. coli membranes
expressing truncated turkey CYP3A37. Km and Vmax of exo-AFBO formation are
21.6 + 6.4 μM and 1.3 + 0.1194 nmol/min/nmol P450, respectively (R2 = 0.746).
Points are mean (± SE), n = 3.

55
CHAPTER 3
CLONING, EXPRESSION, AND FUNCTIONAL CHARACTERIZATION OF
CYTOCHROME P450 3A37 WITH HIGH AFLATOXIN B1 EPOXIDATION
ACTIVITY FROM TURKEY LIVER3
Abstract
Cytochromes P450 (P450) play an important role in the formation of
carcinogenic and mutagenic electrophilic intermediates from a wide range of
xenobiotics, including naturally occurring dietary compounds. The pathogenesis
of hepatotoxic and hepatocarcinogenic action of the mycotoxin aflatoxin B1
(AFB1) involves initial bioactivation by P450s to a reactive and electrophilic
intermediate exo-aflatoxin B1-8,9-epoxide (exo-AFBO). Poultry, especially turkeys
are extremely sensitive to AFB1, a condition due, in part, to efficient epoxidation
by P450 1A and 3A isoforms. We previously reported discovery of CYP1A5 from
turkey liver, that like its human homologue, CYP1A2, bioactivated AFB1 to exoAFBO and aflatoxin M1 (AFM1). Here we describe CYP3A37, the CYP3A4
homologue from turkey liver. The gene has an open reading frame (ORF) of 1512
bp, and the protein is predicted to be 504 amino acids with 97% identity to
chicken CYP3A37. A truncated construct of the turkey CYP3A37 with 11 amino
acids deleted from the hydrophobic N-terminal region was heterologously
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expressed in Escherichia coli, the protein from which exhibited a CO difference
spectrum typical of P450s. Like human CYP3A4, CYP3A37 biotransformed AFB1
to exo-AFBO and aflatoxin Q1 (AFQ1) and possessed nifedipine oxidase activity,
both of which were inhibited by the CYP3A4 inhibitor 17α-ethynylestradiol.
Oxidation of AFB1 to exo-AFBO and AFQ1 by CYP3A37 followed sigmoidal Hill
kinetics best described by Eadie-Hofstee plots, suggestive of an allosteric
interaction between the enzyme and AFB1. CYP3A37 possessed at least two
binding sites (n = 1.9 for exo-AFBO and 1.6 for AFQ1 products) for AFB1,
indicative of positive cooperativity. The calculated Km and Vmax values for the
formation of exo-AFBO were 287 + 21 µM and 1.45 + 0.07 nmol/min/nmol P450,
respectively, whereas those of AFQ1 formation were 302 + 51 µM and 7.86 + 0.75
nmol/min/nmol P450, respectively. These data strongly suggest that CYP3A37,
along with CYP1A5, plays an important role in AFB1 epoxidation in turkey liver.
And, this activity plus that of CYP1A5, previously described, likely results in the
efficient bioactivation of AFB1 that makes turkeys very susceptible to toxicosis.
Introduction
Cytochrome P450s (P450 for protein; CYP for gene) are the major drug
metabolism enzymes involved in the metabolism of variety of endogenous and
exogenous substrates (Parikh et al., 1997). While converting most of the
compounds into readily excretable detoxified hydrophilic form, P450s also
contribute to the toxicity of some xenobiotics through bioactivation resulting in
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the formation of reactive intermediates which causes toxic effects (Guengerich et
al., 1996a). The carcinogenic mycotoxin aflatoxin B1 (AFB1) is bioactivated by
P450s to the electrophilic and highly reactive epoxide intermediate exo-AFB1-8,9epoxide (exo-AFBO) (Ball and Coulombe, 1991; Coulombe, 1993; Gallagher et al.,
1996; Guengerich et al., 1996a), which binds to DNA, RNA and cellular proteins
and is responsible for mediating the toxic and carcinogenic effects of AFB1 in
humans as well as most animal species. In many species, glutathione-Stransferases (GSTs) detoxify the exo-AFBO so produced, by conjugating it with
endogenous glutathione.
Poultry, specifically turkeys, are extremely sensitive to aflatoxicosis
(Carnaghan et al., 1966; Arafa et al., 1981; Giambrone et al., 1985; Huff et al., 1986;
Kubena et al., 1995; Klein et al., 2000). The susceptibility of turkeys to AFB1 was
first demonstrated in the early 1960s as the etiological agent of “Turkey X
disease” which caused widespread deaths of turkeys and other poultry in
Europe (Stevens et al., 1960). Aflatoxins are ubiquitous in corn-based animal
feeds, their presence in feed cause significant economic losses to the poultry
industry every year, and contamination is practically unavoidable (CAST, 1989;
Coulombe et al., 2005).
We have previously shown that this extreme sensitivity of turkeys to
AFB1, is, in part, due to efficient oxidation mediated by homologues to human
CYP1A2 and CYP3A4 (Klein et al., 2000, 2003; Yip and Coulombe, 2006). We
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recently amplified CYP1A5 from turkey liver (Yip and Coulombe, 2006), the E.
coli expressed protein of which, like its human counterpart CYP1A2, oxidized
AFB1 to exo-AFBO and aflatoxin M1 (AFM1). Although both P450 1A and 3A
enzymes oxidize AFB1, there are conflicting reports on their relative importance
(Shimada and Guengerich, 1989; Ramsdell and Eaton, 1990; Gallagher et al., 1994,
1996). In human liver, CYP3A4, which appears to account for the majority of the
formation of exo-AFBO and AFQ1, was an important determinant of the AFB1
disposition (Shimada and Guengerich, 1989; Kamdem et al., 2006).
We recently elucidated the genetic structure of turkey CYP3A37, which
like human CYP3A4, is organized into 13 exons and 12 introns (see Chapter 2).
The exons of the turkey gene were 124, 94, 53, 100, 114, 89, 149, 128, 73, 161, 227,
163, and 475 bases in length. Exons 1 and 13 contained 71 and 93 coding
nucleotides, respectively. Because of its presumed role in AFB1 bioactivation, we
describe here the heterologous expression and functional characterization of this
CYP3A4 homologue, CYP3A37.
Materials and Methods
Chemicals and Reagents. QIAprep spin miniprep kit, QIAquick PCR
purification kit, and gel extraction kit were obtained from Qiagen (Valencia, CA).
TOPO TA cloning kit and maximum efficiency DH5αF‟IQ Escherichia coli cells
were from Invitrogen (Carlsbad, CA). Restriction enzymes and T4 DNA ligase
were from Fermentas (Hanover, MD). Exo- and endo-AFB1-8,9-epoxide
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glutathione conjugate (AFBO-GSH) standard were a generous gift from Dr. F.
Peter Guengerich, Vanderbilt University School of Medicine (Nashville, TN).
Anti-His tag monoclonal antibody was from Novagen (San Diego, CA). The
Phototope-HRP Western Blot Detection System was from Cell Signaling
(Beverley, MA). Rabbit polyclonal anti-CYP3A37 serum was raised against the
peptide sequence “SQKSDSDGKNSHKA” (amino acids 278-291) by Genemed
Synthesis (San Antonio, TX). This peptide sequence was selected by the
manufacturer while taking into consideration that it should be antigenic,
hydrophilic and readily accessible. All other chemicals were purchased from
Sigma-Aldrich (St. Louis, MO).
Rapid amplification of cDNA ends (RACE). The CYP3A37 gene was
amplified from 1-day-old male turkey liver by 3‟-5‟-RACE procedures described
previously (Yip and Coulombe, 2006; Chapter 2). In brief, small segments of
RNA later stored turkey liver were homogenized and RNA isolated using Poly
(A) Pure mRNA purification kit (Ambion, Austin, TX). Isolated RNA was further
used as a RACE template. The RACE procedure as mentioned in BD SMART
RACE cDNA Amplification Kit (BD Biosciences Clontech, Palo Alto, CA) was
followed. Primers used in 3‟-RACE were designed based upon the sequence
alignment of CYP3A4 in human and cattle, 3A4v2 in Cercopithecus aethiops
(African green monkey), 3A44 in mouse, 3A66 in Macaca mulatta (rhesus monkey)
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and 3A45 in Onchorhynchus mykiss (rainbow trout) 4 using ClustalW
(www.ebi.ac.uk). 5‟-RACE primers were designed based on sequences of 3‟RACE as well as the sequence alignments. Products of the PCR were cloned into
pCR 4-TOPO vector and sequenced at the CORE facility at Utah State University.
Sequences were analyzed by Lasergene SeqMan II software (DNASTAR Inc.,
Madison, WI).
Construction of expression plasmid and bacterial expression. An E. coli
based recombinant P450 system was used for CYP3A4 homologue identification
(Yip and Coulombe, 2006). Expression vector construction was as described
previously (Yip and Coulombe, 2006). We chose pCW vector, developed by the
laboratory of Prof F. W. Dahlquist (Gegner and Dahlquist, 1991), which contains
two tac promoter (inducible by isopropyl-β-D-thiogalactopyranoside: IPTG)
cassettes upstream of an NdeI (CATATG) restriction enzyme cloning site
coincident with the initiation ATG codon. This vector contains a strong
transcription termination mechanism and a phage M13 origin of DNA
replication. Transcription prior to the addition of inducing agents is inhibited by
LacI gene encoding a lac repressor molecule. The original bicistronic
pCW1A2/hNPR vector developed by Dr. F. Peter Guengerich was generously
provided by Dr. Gary Yost, University of Utah (Salt Lake City, UT). Bicistronic
GenBank accession numbers for the CYP3A enzymes cited in this article are as follows: Human
CYP3A4: BC069418, Bos taurus (cattle): NM_174531, Cercopithecus aethiops (African green
monkey): DQ022198, Mus musculus (house mouse): AB039380, Macaca mulatta (rhesus monkey):
AY635466, Oncorhynchus mykiss (rainbow trout): AF267126.
4
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expression constructs consisting of the coding sequence of CYP3A37 followed by
human NADPH-P450 reductase (hNPR), the redox partner to P450, were
constructed as described (Yip and Coulombe, 2006; Chapter 2). Cytochrome
P450s are difficult to express in their native form due to the hydrophobic amino
acid rich N-terminal region, so a truncated version of the gene was constructed
to enhance its expression in E. coli (Barnes et al., 1991) (Figure 3.1). Specifically 11
codons were deleted in the N-terminus and the first 8 codons had a modified
nucleotide sequence to enhance its expression. A 6X-His tag was added in the Cterminal region to facilitate immunodetection and purification (Crowe et al.,
1994). The original pCW1A2/hNPR vector was digested with NdeI and XbaI to
excise the CYP1A2 coding sequence for the construction of expression constructs.
Clones of CYP3A37 digested with NdeI and XbaI were ligated with the gelpurified vector fragment and PCR-amplified using T4 DNA ligase. This ligation
mix was transformed into DH5αF‟IQ cells. Heterologous expression of CYP3A37
in E. coli was performed (Jenkins et al., 1998). A single colony of DH5αF‟IQ E. coli
transformants was inoculated in to five milliliters of Luria-Bertani ampicillin
medium. It was then allowed to grow overnight at 37 ºC with vigorous shaking.
450 mL of modified Terrific-Broth ampicillin medium with trace elements was
then used for further inoculation of the starter culture at 1:100 dilutions. Cultures
were grown at 37 ºC to an OD600 of 0.3-0.5. After an equilibration step of 30 min
at 30 ºC, induction was initiated by adding 1 mM IPTG. δ-aminolevulinic acid
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(0.5 mM) was also added to the cultures. Cells were incubated at 30 ºC with
shaking (150 rpm), harvested after 23 h and amounts of P450 expression were
determined by reduced CO/reduced difference spectra (Omura and Sato, 1964)
(Spectronic GENESYS 6 UV-Vis spectrophotometer, Thermo Spectronic,
Rochester, NY). E. coli membranes and cytosol were prepared as described (Yip
and Coulombe, 2006). All kinetic assays were performed with CYP3A37 E. coli
membranes.
Immunodetection of recombinant CYP3A37. E. coli membranes
expressing CYP3A37, control vector (pCWOri+ without P450 and reductase
inserts) and turkey liver microsomes were run on a 4-15% Tris-HCl Ready Gel
(Bio-Rad). Immunoblotting was performed according to the supplier‟s
instructions (Qiagen, Valencia, CA). To reduce the extraneous bands caused by
the recognition of bacterial proteins, the rabbit polyclonal anti-CYP3A37 serum
was first preadsorbed by pCWOri+ E. coli membranes (Guengerich et al., 1996b;
Yip and Coulombe, 2006). Briefly, 120 µL of pCWOri+ membranes (22 mg
protein) were added to 2 mL antiserum (111 mg protein) and incubated at 4 ºC
for 2.5 h for preadsorption. The samples were centrifuged at 13000g for 10 min at
4 ºC and supernatants were used as primary antibody (1:4000). HRP-conjugated
goat anti-rabbit IgG (1:5000) were used as secondary antibody.
Chemiluminescence (SuperSignal West Pico Chemiluminescent Substrate, Pierce,
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Rockford, IL) signal detection and images were captured using Nucleovision E20
Imaging Workstation (Nucleotech, Hayward, CA).
Quantification of AFB1 metabolites. The exo-AFBO intermediate is
unstable and has a short half-life, so it was determined indirectly as a stable,
trapped AFBO-GSH conjugate using conditions we have described previously
(Ramsdell and Eaton, 1990; Yip and Coulombe, 2006). A reaction mixture
consisting of E. coli membranes expressing CYP3A37 (0.709 µM), butylated
hydroxyanisole (BHA)-induced mouse cytosol (~800 µg total protein) as a source
of GST, 2 mM NADPH, 5 mM GSH and 0.1-1000 µM AFB1 in spectral grade
dimethyl sulfoxide (DMSO) was made in epoxide trapping buffer (5 mM MgCl2,
25 mM KCl, 0.25 mM sucrose, and 80 mM potassium phosphate, pH 7.6) to give a
final volume of 250 µL. The reactions were incubated at 37 ºC for 20 min with
gentle shaking and stopped by adding 250 µL of cold methanol spiked with 24
µM aflatoxin G1 (AFG1) as an internal standard. Inhibitor or anti-CYP3A37
antibodies whenever used were incubated with the membranes for 10 min in an
ice-bath before adding other components of the reaction. This treatment was
done to provide extra time for the inhibitor or the antibody to bind to the
enzyme. The samples were kept overnight at -20 ºC to facilitate protein
precipitation and then centrifuged at 13000g for 10 min. The supernatant was
filtered through a 0.2 µm nylon membrane before 100 µL was injected into the
HPLC. Metabolites were separated on a Shimadzu LC system (Shimadzu,

64
Pleasanton, CA) equipped with a model LC-20AD pump, a model SPD-20AV
UV-Vis detector, and an Econosphere C18 (150 mm X 4.6 mm) column (Alltech
Associates, Deerfield, IL) which was kept at 40 ºC. The eluate was monitored by
UV absorbance (λ = 254 nm). The mobile phases used in this assay were as
described previously (Klein et al., 2000). Metabolites were quantified by
establishing calibration curves between the peak areas in the chromatograms and
the amounts of metabolites injected, using authentic AFBO-GSH and AFQ1
standards.
Nifedipine oxidase activity. Nifedipine oxidase was determined as
described previously (Kelly et al., 1997). Inhibitors or anti-CYP3A37 antibodies
were tested on this activity in a similar way as described above.
Data analysis. Kinetic data were analyzed by SigmaPlot Enzyme Kinetics
Module software (Systat, San Jose, CA). Data for exo-AFBO and AFQ1 formation
were analyzed by nonlinear regression using the general allosteric model, the
Hill equation to calculate Vmax and Km [V= Vmax [S]n/ ([Km]n + [S]n)]. In this
equation, n represents the number of apparent binding sites.
Results
RACE. Sequence analysis revealed that this gene has an ORF of 1512 bp
coding for 504 amino acids. In addition, it had 53 bp in the 5‟-untranslated region
(UTR) and 384 bp in the 3‟-UTR, with a total of 1949 bp (Figure 3.2). Predicted
molecular mass of this CYP3A4 homologue is 58 kDa. The heme-binding motif,
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usually represented as FXXGXXXCXG, was identified in CYP3A37 as
FGAGPRNCIG (Figure 3.2). Sequence identity comparison of this gene and
CYP3A class genes in other species is shown in Table 3.1. These comparisons,
which were made using EMBOSS-Align program (www.ebi.ac.uk), revealed that
this gene has 93% and 92% nucleic acid and amino acid identity, respectively, to
the chicken CYP3A37 (Ourlin et al., 2000), and was thus assigned as CYP3A37 by
Dr. David Nelson of the University of Tennessee.
Bacterial Expression and Immunodetection. As frequently observed with
unmodified P450s (Guo et al., 1994), the wild-type CYP3A37 was not expressed
as detectable P450 as determined by reduced CO/reduced difference spectrum
(Omura and Sato, 1964). The truncated tCYP3A37 expressed 250-400 nmol of
CYP3A37 per liter of the culture, as determined by the CO difference spectra of
whole cells. CYP3A37 was recovered in both membrane and cytosol,
approximately 26% and 25-45%, respectively. The rest of the amounts were lost
in differential centrifugation procedure used for the isolation of membrane and
cytosolic fractions. E. coli membranes expressing recombinant CYP3A37 also
expressed active hNPR (0.54 µmol/min/mg total protein) as measured by
cytochrome c reduction. As compared to the activity of purified hNPR expressed
in E. coli from the same plasmid (50 µmol/min/mg), we determined that hNPR
was comprised of 2.8% (w/w) of the proteins in tCYP3A37 E. coli membrane (vs
8% for P450), which corresponded to a hNPR-to-P450 molar ratio of about 1:4.
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Polyclonal anti-CYP3A37 antibodies detected a band with an apparent molecular
mass of 58 kDa in E. coli expressed CYP3A37 and in turkey liver microsomes
(Figure 3.3).
AFB1 Oxidation and Nifedipine Oxidase activity. E. coli-expressed
CYP3A37 oxidized AFB1 to exo-AFBO and AFQ1, and a plot of V vs. S, exhibited a
sigmoidal relationship, suggesting that the formation of both products is driven
by an allosteric interaction between AFB1 and CYP3A37, showing positive
cooperativity (Figure 3.4A). The data were analyzed by the general allosteric
model using the Hill equation, and the resultant Eadie-Hofstee plots are shown
in Figures 3.4B (for exo-AFBO formation) and 3.4C (AFQ1). The n (apparent
number of binding sites) values for the formation of exo-AFBO and AFQ1 were
1.9 and 1.6, respectively, suggesting the presence of at least two binding sites for
AFB1 on CYP3A37 (Table 3.2). The mean dissociation constant (Km) for the two
sites was 295 µM.
Like human CYP3A4 (Yamazaki et al., 1996), CYP3A37 possessed
nifedipine oxidase activity which, unlike AFB1 metabolism, conformed to simple
Michaelis-Menton kinetics. The Km and Vmax for this activity were 1.4 + 0.5 µM
and 1465 + 289 nmol/min/nmol P450 (r2 = 0.84), respectively (Figure 3.5).
Inhibition by specific P450 inhibitors and anti-CYP3A37 antibodies. The
effects of specific inhibitors to mammalian P450s on exo-AFBO formation as well
as on nifedipine oxidase activity were examined. The specific CYP3A4 inhibitor
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17α-ethynylestradiol was the most effective of those tested, completely inhibiting
the formation of exo-AFBO at a concentration of 200 µM (IC50 = 40 µM) (Figure
3.6). Erythromycin, a CYP3A1/4 inhibitor was moderately effective. Inhibitors to
other P450s were either slightly or not effective (Figure 3.6). At the same
concentrations, 17α-ethynylestradiol also inhibited nifedipine oxidase activity
(IC50 = 74 µM) (Figure 3.7). Anti-CYP3A37 antibodies inhibited the formation of
both exo-AFBO and nifedipine oxidase activity, as shown in Figure 3.8.
Discussion
Many P450s bioactivate xenobiotics, like AFB1, converting them into
highly reactive electrophilic intermediates, which cause mutation and
carcinogenesis. Although AFB1 is metabolized by P450s to endo- and/or exoAFBO, it is the exo- stereoisomer which binds to DNA, RNA and other cellular
macromolecules to elicit the toxic responses to this mycotoxin (Raney et al., 1992).
The extreme sensitivity of turkeys to AFB1 is due, at least in part, to hepatic P450s
with high epoxidation activity. In turkey liver microsomes, both CYP1A and 3A
homologues are responsible for the metabolism of AFB1 to the toxic and
carcinogenic exo-AFBO, as it occurs in humans and other animals (Klein et al.,
2000; Yip and Coulombe, 2006; Chapter 2). Here, we report that turkey liver
possesses CYP3A37, a homologue to human CYP3A4 with AFB1 epoxidation and
nifedipine oxidase activity.

68
The nucleic acid sequence of this gene was remarkably similar to chicken
CYP3A37 (Ourlin et al., 2000), with 93% identity. While the sequence of this gene
was 66% identical to human CYP3A4, the catalytic activity of the E. coli expressed
CYP3A37 closely resembled that of its human counterpart. Turkey CYP3A37
possessed activity towards prototypical CYP3A4 substrate nifedipine (Yamazaki
et al., 1996) and also oxidized AFB1 in a manner similar to human CYP3A4
(Gallagher et al., 1996). Inhibition of the catalytic activities of CYP3A37 by 17αethynylestradiol further support it‟s designation as a CYP3A4 homologue.
Generally P450s require alterations in the hydrophobic N-terminal
nucleotide sequence (5‟- end) to facilitate translation by E. coli (Barnes et al.,
1991). The N-terminal truncated sequence of wild-type CYP3A37 was produced
by deleting 11 codons and modifying the nucleotide sequence of the first 8
codons to facilitate translation by E. coli. These modifications are reported to
reduce the free energy for base pairing while inhibiting the formation of
secondary structures by mRNA, which could inhibit translation (Guengerich et
al., 1996a). Subsequently, truncated CYP3A37 expressed in E. coli produced
substantial amounts of active P450, which was confirmed by immunoblots
showing a band of apparent molecular mass of about 58 kDa. The addition of
hNPR, in our bicistronic constructs, ensured efficient electron transfer to P450:
the hNPR-to-P450 ratio in the E. coli membranes was 1:4, similar to that we
previously reported for turkey CYP1A5 (Yip and Coulombe, 2006) and greater
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than previously reported ratios of 1:5-20 in mammalian liver microsomes
(Estabrook et al., 1971; Shephard et al., 1983; Parikh et al., 1997).
Striking similarities between the catalytic activities of E. coli expressed
turkey CYP3A37 and human CYP3A4 were observed. For example, turkey
CYP3A37 efficiently metabolized AFB1 to exo-AFBO and AFQ1 and also
possessed nifedipine oxidase activity, as does the human enzyme. Furthermore,
these catalytic activities were completely inhibited by CYP3A4 specific inhibitor
17α-ethynylestradiol. It must be emphasized that P450 prototypical substrates
and inhibitors used in this study were developed for mammalian P450s, and
specificities of these compounds for avian P450s have not been rigorously
validated. Erythromycin, an inhibitor to CYP3A1/4, also inhibited the formation
of exo-AFBO as well as nifedipine oxidase activity, but at concentrations higher
than that observed for 17α-ethynylestradiol (> 800 µM). While 17αethynylestradiol efficiently inhibited catalytic activities of CYP3A37,
erythromycin was moderately effective, which may be explained by interspecies
differences among P450 enzymes.
This metabolic specificity of CYP3A37 confirms our previous observation
of the involvement of a CYP3A4 homologue (along with a CYP1A2 homologue)
in AFB1 bioactivation in turkey liver microsomes (Klein et al., 2000; Yip and
Coulombe, 2006). Similar to what we previously reported for CYP1A5, turkey
CYP3A37 resembled its human counterpart with respect to metabolite profile,
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and to the kinetics of AFB1 oxidation. Like human CYP3A4, CYP3A37 catalysis of
AFB1 is driven by an allosteric interaction, showing positive cooperativity.
Human CYP3A4 is reported to have a large and conformationally dynamic active
site which can accommodate multiple substrates or effector molecules, the
binding of which leads to allosteric kinetic behavior in that substrate binding to
CYP3A4 facilitates binding of additional molecules of substrate, enhancing
turnover (Roberts and Atkins, 2007). Similar to human CYP3A4 (Gallagher et al.,
1996), CYP3A37 possessed at least two binding sites for AFB1.The Km values
determined for CYP3A37 were almost two-fold greater than those for human
CYP3A4 [302 µM vs. 139 µM for AFQ1; 287 µM for exo-AFBO in our study vs. 133
µM for AFBO reported by (Gallagher et al., 1996)], though this comparison is not
accurate since those authors (Gallagher et al., 1996), did not distinguish the endoand exo- isomers. The Vmax value of AFQ1 formation was almost 8-fold lower for
CYP3A37 than those of human CYP3A4 (7.86 vs. 61 nmol/min/nmol P450),
while that of exo-AFBO formation in our study was more than 4-fold lower than
that of the AFBO formation measured for human CYP3A4 (1.45 vs. 6.2
nmol/min/nmol P450) (Gallagher et al., 1996). Such kinetic differences could be
explained by interspecies variations of P450s, but is more likely due to different
in vitro systems used to model enzyme activity.
Although CYP3A37 and turkey CYP1A5 (Yip and Coulombe, 2006),
exhibited different kinetics, a comparison of the kinetic constants of exo-AFBO
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formation suggests that the former may be more efficient. The Vmax of CYP3A37
is more than two times that of CYP1A5 (1.45 + 0.07 vs. 0.61 + 0.04
nmol/min/nmol P450). However, it must be emphasized that the affinity of
CYP3A37 for AFB1 may be 4-fold lower than that of CYP1A5, as indicated by
their Km values (287 ± 21 vs. 65 + 12 µM).
While there are conflicting reports as to which isoform is more important
in humans in activating AFB1 (Shimada and Guengerich, 1989; Ramsdell and
Eaton, 1990; Gallagher et al., 1994, 1996), some reports suggest that human
CYP1A2 is more active at submicromolar substrate concentrations because of its
high affinity for AFB1, whereas CYP3A4 activates AFB1 at higher concentrations
(>50 µM) (Crespi et al., 1991; Gallagher et al., 1996). Indeed a similar finding was
observed previously in our laboratory in human bronchial cells expressing CYP
1A2 and 3A4 (Van Vleet et al., 2002).
In conclusion, CYP3A37 is important in mediating toxicity of AFB1 in
turkeys. This gene was heterologously expressed in E. coli, in quantities sufficient
to support the catalytic activities, which were similar to the human CYP3A4.
Because of the role of human CYP3A4 in AFB1 oxidation to exo-AFBO (Shimada
and Guengerich, 1989; Gallagher et al., 1996; Kamdem et al., 2006), we believe that
the identification of this homologue from turkeys is important in discerning the
mechanisms of extreme sensitivity of this species to AFB1. Of particular
importance was the metabolism of AFB1 by the E. coli expressed protein to exo-
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AFBO and AFQ1. Exo-AFBO, a highly reactive electrophilic intermediate, is
responsible for carcinogenic and mutagenic effects of AFB1. Thus, we conclude
that CYP3A37 along with CYP1A5 plays an important role in the extreme
sensitivity of turkeys to AFB1.
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Table 3.1. Nucleic acid and amino acid sequence identity and similarity between
turkey CYP3A37 and other CYP3As (EMBOSS-Align).
Nucleic acid

Amino acid

Cytochrome P450

Species

% Identity

% Identity

% Similarity*

CYP3A37
CYP3A
CYP3A13
CYP3A13
CYP3A4
CYP3A5

Chicken
Xenopus
Rat
Mouse
Human
Human

93
64
67
67
66
66

92
56
62
60
58
58

97
75
79
79
76
76

*Percentage similarity of amino acid sequence was determined based on
EBLOSUM62 matrix.
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Table 3.2. Hill Equation kinetic constants for CYP3A37 catalyzed AFB1 oxidation
in E. coli expressed CYP3A37, at AFB1 concentrations of 0.1-1000 µM. “n” is
number of apparent binding sites. Vmax and Km measured as nmol/min/nmol
Metabolite

Vmax ± SE*

Km ± SE*

n ± SE*

R2

exo-AFBO

1.45 ± 0.07

287 ± 21

1.9 ± 0.18

0.98

AFQ1

7.86 ± 0.75

302 ± 51

1.6 ± 0.26

0.96

P450 and μM, respectively.
*3 replicates were used
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wtCYP3A37:5’- ATGAATTTATTACCTTTTTTTTCTATTGAAACCTGGATACTCTTG
M N L L P F F S I E T W I L L
tCYP3A37: 5’- ATGGCT
M A

11 amino acids deleted

TTATTA
L L

wtCYP3A37:

CTTATTTTTGTAGCCCTCCTGATAGCATATGGAACATGGCCATTT
L I F V A L L I A Y G T W P F

tCYP3A37:

TTAATTTTTGTAGCCCTCCTGATAGCATATGGAACATGGCCATTT
L I F V A L L I A Y G T W P F

wtCYP3A37:

----------

AATGCCAAGGCACATCACCATCACCATCACTGA-3’
N A K A H H H H H H STP

----------

AATGCCAAGGCACATCACCATCACCATCACTGA-3’
N A K A H H H H H H STP

510aa not shown

tCYP3A37:

Figure 3.1. Expression constructs of CYP3A37 showing nucleic acid and amino
acid sequences at the N- and C-terminals. Wild-type (wtCYP1A5) has 1512 bp
encoding 504 amino acids; the truncated construct (tCYP1A5) has 1479 bp
encoding 493 amino acids. Six histidines were added at the C-terminals to
facilitate detection and purification. Nucleotides and amino acids different from
the wild type sequence are bolded.
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M N L L P F F S I
AGATGGACAGAGACATACGGACAGACCTCCAAGCCAACTAGAGGAGAGCCACGATGAACCTTCTTCCTTTCTTCTCCATT
E T W I L L L I F V A L L I A Y G T W P F G L F K K L
GAAACCTGGATCCTCTTGCTTATTTTTGTAGCCCTCCTGATAGCATATGGAACATGGCCATTTGGGCTGTTCAAGAAGCT
G I P G P R P L P F F G T C L E Y R K G F L E F D T E
GGGCATTCCTGGGCCAAGACCTCTGCCTTTCTTTGGGACGTGCCTGGAATACCGTAAAGGCTTCTTGGAATTTGACACTG
C F K K Y G K I W G I Y D G R Q P A V V V M D P Q I
AGTGCTTCAAGAAGTATGGGAAAATCTGGGGGATTTACGATGGCAGGCAGCCTGCAGTGGTTGTCATGGACCCCCAGATC
I K T V L V K E C Y S T F T N R R R V D L A G E L R N
ATCAAAACCGTGCTGGTGAAAGAGTGCTACTCCACCTTCACCAACCGCAGGCGCGTAGATCTAGCAGGGGAGCTGAGAAA
A V S L A E D D Q W K R L R T V L S P T F T S G K L K
TGCTGTCTCATTAGCTGAAGACGATCAGTGGAAAAGGCTCCGTACTGTGCTCTCTCCAACCTTCACCAGTGGGAAGCTAA
E M F P T M K H F G E M L V K N V Q K R V E K D S S
AGGAGATGTTTCCTACAATGAAGCACTTTGGGGAGATGTTGGTGAAAAATGTTCAAAAGAGGGTGGAAAAGGACAGCTCT
V P V K D F F G S Y S M D V V T S T S F G V N I D S M
GTCCCTGTGAAGGACTTCTTTGGAAGCTACAGCATGGATGTAGTCACCAGCACTTCCTTCGGTGTGAACATCGACTCCAT
N N P K S P F V R E M Q K L T K F D F F D P L F I L A
GAACAACCCTAAAAGCCCCTTTGTCAGAGAGATGCAGAAACTGACCAAGTTTGATTTTTTTGATCCACTCTTCATCTTGG
F V C P F L T P L M A K M N V S F F P S D A V D F F
CATTTGTATGCCCATTCCTTACCCCTCTTATGGCCAAGATGAACGTCAGCTTTTTCCCAAGTGATGCTGTAGATTTCTTC
L R S I D K I K K D R E K E T H K G R V D F L Q M M I
CTGAGGTCTATTGACAAAATTAAGAAGGACCGTGAAAAGGAGACTCACAAGGGCAGAGTAGATTTTCTGCAGATGATGAT
E S Q K S D S D G K N S H K A L S D I E V L S Q A F I
CGAATCCCAGAAATCAGACAGCGATGGGAAGAACTCACATAAAGCCCTGAGTGACATAGAGGTCCTGTCACAAGCATTCA
F I F A G Y E P T S N T L C Y L A Y L L A L H P D V
TCTTCATTTTTGCTGGCTATGAGCCCACCAGTAACACACTTTGTTACCTGGCTTACCTGCTGGCCTTGCATCCTGATGTA
Q Q K V V N E I D T I L P N K A P L T Y E A I M Q L D
CAGCAGAAGGTGGTGAATGAAATAGATACCATTCTACCCAACAAGGCTCCGCTCACATATGAAGCGATAATGCAGTTGGA
Y L D M A V N E T L R L Y P L G G R I E R T C K K D V
TTACCTTGACATGGCCGTGAATGAAACCCTCCGGCTCTATCCCCTCGGAGGACGGATTGAGAGAACCTGCAAGAAAGATG
E I N G V T I P K E T I V V I P P Y T L H R N S E Y
TGGAAATAAACGGGGTGACCATTCCAAAAGAAACCATTGTCGTTATCCCACCTTACACCCTGCACCGCAACTCCGAGTAC
W P N P E E F R P E R F S K E N K D N I D P Y T Y L P
TGGCCAAACCCAGAGGAGTTCAGACCAGAAAGGTTCAGTAAGGAAAACAAAGACAACATAGACCCATACACATACCTGCC
F G A G P R N C I G M R F A L L T L K V A I T S I L Q
TTTTGGAGCTGGTCCCAGGAACTGCATTGGGATGCGATTTGCTCTCTTGACTCTGAAAGTTGCCATCACTTCCATATTGC
H F T F Q V C K E T Q I P L K L L S M G L M T P E K
AGCACTTCACCTTCCAGGTCTGCAAAGAAACTCAGATCCCTCTCAAGCTGCTCTCGATGGGACTCATGACTCCAGAGAAG
P I I L K L V P R T N N A K A *
CCCATCATTCTCAAGTTAGTCCCTCGGACCAACAATGCCAAGGCATAGAACCCAACTGTGTCCTGCTGCAGTCTAATGAA

80
160
240
320
400
480
560
640
720
800
880
960
1040
1120
1200
1280
1360
1440
1520
1600

CCCTATGCTAACAAAGGGGTCACACACTGCAGGAAAACTCTCATACGTGTGCAGACACAGAAGTGCAACTTAGCTAATTC 1680
TAGAAGCAATTACTACATATTTACCAAATAACAGCTGTCAGAAATGTAATGTGGATCACTGGGCAGTGGCAATGCACAGC 1760
CCCCTTCATTTGATTGCAGAAATTGAGAAATAAATCCAAATGAGAAGCTGATCATCCACTCCCTTCTAAGGAGACTTCTC 1840
CATCTGGAAAGAAGGAATTATTGTGGCATTCAAGAGAAACAAGGTGTGATGGAAACGCAAATCGCTAGAGCTCGCTGGGC 1920
AGAGATGGGTGACTTTCTTCTTGGTGTAC

1949

Figure 3.2. Complete cDNA and predicted amino acid sequence of turkey
CYP3A37, with 5‟- and 3‟-UTRs. ORF: 1512bp encoding 504 aa; 5‟-UTR: 53 bp; 3‟UTR: 384 bp; total cDNA length: 1949 bp. Start and stop codons are bolded, the
heme-binding motif, usually represented as FXXGXXXCXG is underlined.
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Figure 3.3. Immunoblot showing 60 kDa bands in both turkey liver microsomes
and in CYP3A37-expressing E. coli membranes. A minor band which was
detected at around 80 kDa was presumably a bacterial protein, present in E. coli
membranes of CYP3A37 and in those of pCWOri+ (the empty vector control).
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Figure 3.4. Kinetics of AFB1 oxidation by E. coli expressed CYP3A37. A sigmoidal
relationship between substrate concentration and product formation was
observed, suggesting exo-AFBO and AFQ1 formation are driven by an allosteric
interaction between CYP3A37 and AFB1, showing positive cooperativity. The
data was analyzed by Hill‟s equation. (A) V vs. S plot of exo-AFBO and AFQ1
formation (B) Eadie-Hofstee plot of exo-AFBO formation (C) Eadie-Hofstee plot
of AFQ1 fromation. Points are mean (+ SE), n=3.
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Figure 3.5. Nifedipine Oxidase activity of E. coli membranes expressing
CYP3A37. Activity followed Michaelis-Menton kinetics with parameters: Vmax =
1465 + 289 nmol min/ nmol/ P450, Km = 1.4 + 0.5 µM (R2 = 0.84). Points are mean
(+ SE) (n=3).
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Figure 3.6. Inhibition of AFB1 oxidation to exo-AFBO by E. coli expressed
CYP3A37, using specific inhibitors to P450s. CYP3A4 prototype inhibitor 17αethynylestradiol inhibited formation of exo-AFBO (IC50 = 40 µM). Erythromycin
was less efficient. Inhibitors to other mammalian CYPs were either slightly or not
effective. Points are mean (n=3).
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Figure 3.7. Inhibition of nifedipine oxidase activity of E. coli expressed CYP3A37
by specific inhibitors to P450s. 17α-ethynylestradiol, a specific inhibitor to
CYP3A4 inhibited nifedipine oxidase activity of E. coli expressed CYP3A37 (IC50
= 74 µM). Erythromycin was less effective. Points are mean (n=3).

85

Figure 3.8. Inhibition of CYP3A37 mediated AFB1 epoxidation and nifedipine
oxidase activity by anti-CYP3A37 antibodies (5 µg/ml/nmol P450). Points are
mean (n=3).

86
CHAPTER 4
METABOLISM OF AFLATOXIN B1 IN TURKEY LIVER MICROSOMES: THE
RELATIVE ROLES OF CYTOCHROME P450S 1A5 AND 3A37
Abstract
The extreme sensitivity of turkeys to aflatoxin B1 (AFB1), is associated with
an efficient epoxidation by hepatic microsomal cytochrome P450s 1A5 and 3A37
to the toxic exo-aflatoxin B1-8,9-epoxide (exo-AFBO). The combined presence of
1A5 and 3A37 in the turkey liver, both of which metabolize AFB1 to the exoAFBO and to detoxification products AFM1 and AFQ1, respectively, complicates
the kinetic analysis of the oxidation of this mycotoxin in turkey liver microsomes
(TLMs). Furthermore, 1A5 and 3A37 follow Michaelis-Menton and Hill‟s
kinetics, respectively. In the present study, we examined the reaction kinetics of
AFB1 oxidation in TLMs, using antisera directed against CYP1A5 and 3A37, for
the purpose of identifying the isoform responsible for epoxidating AFB1 at
relatively low concentrations. Pretreatment with anti-CYP1A5 inhibited exoAFBO formation, which was especially marked at low, submicromolar (~0.1 µM),
while anti-CYP3A37 immune serum inhibited exo-AFBO formation, which was
most evident at much higher (> 50 µM) AFB1 concentrations. At 0.1 µM AFB1 ,
which is close to the range seen in the livers of animals exposed to AFB1
concentrations typically occurring in foods and feeds, CYP1A5 contributed to
about 98% of the total exo-AFBO formation. At this concentration, CYP1A5 was
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responsible for a much higher ratio (50:1) of activation to detoxification product
(exo-AFBO: AFM1) compared to CYP3A37. Kinetic constants indicated that
CYP1A5 acts as the higher affinity, while CYP3A37 as the lower affinity isoform
for AFB1. In total, the data presented here support the conclusion that CYP1A5 is
the dominant enzyme responsible for AFB1 bioactivation and metabolism at realworld AFB1 concentrations, and therefore plays an important role in the extreme
sensitivity of turkeys to aflatoxicosis.
Introduction
Aflatoxins, which are toxic and carcinogenic mycotoxins produced by
Aspergillus fungi, are a major public health concern, especially in geographies
where AFB1 contaminated foods constitute a staple diet. Aflatoxin B1 (AFB1) is
the most toxic and carcinogenic of all aflatoxins (Wogan et al., 1974; Wong and
Hsieh, 1976; Bondy and Pestka, 2000). AFB1 is not toxic per se, but requires
bioactivation by P450s to the electrophilic and toxic intermediate exo-AFB1-8,9epoxide (exo-AFBO) (Ball and Coulombe, 1991; Coulombe, 1993; Gallagher et al.,
1996). Poultry, especially turkeys, are extremely sensitive to the toxic effects of
AFB1 (Carnaghan et al., 1966; Arafa et al., 1981; Kubena et al., 1995; Klein et al.,
2000), a condition graphically demonstrated when this mycotoxin was
discovered as the etiological agent of “Turkey X Disease,” responsible for the
deaths of poultry throughout Europe in the 1960s (Smith, 1960). We have
previously shown that the extreme sensitivity of turkeys to AFB1 is associated

88
with efficient hepatic microsomal bioactivation to exo-AFBO by homologues to
human CYP1A2 and 3A4 (Klein et al., 2000; Yip and Coulombe, 2006; Chapter 2;
Chapter 3). We recently cloned, expressed and characterized CYP1A5 (Yip and
Coulombe, 2006) and 3A37 (Chapter 2; Chapter 3) from turkey liver, which, like
the human homologues, produced exo-AFBO, and the detoxified metabolites
AFM1 and AFQ1, respectively. Furthermore, the kinetics of exo-AFBO formation
by CYP1A5 followed Michaelis-Menton kinetics, while those for 3A37 exhibited
sigmoidal Hill‟s kinetics, suggestive of an allosteric interaction between AFB1
and CYP3A37, showing positive cooperativity (Gallagher et al., 1996, Chapter 3).
The relative roles of turkey CYP1A5 and 3A37 in the epoxidation of AFB1 is
uncertain. While the relative importance of human CYP1A2 and 3A4 in AFB1
oxidation has been the subject of disagreement in the literature (Shimada and
Guengerich, 1989; Ramsdell and Eaton, 1990; Ueng et al., 1995; Gallagher et al.,
1996), such studies have never been performed in turkeys. In the present study,
we used antisera directed against CYP1A5 and 3A37 as tools to investigate the
role of these enzymes in bioactivation of AFB1 in turkey liver microsomes
(TLMs). The purpose of this study was to evaluate which of these isoform is
most active at relatively low concentrations of AFB1, more likely to be achievable
in turkey liver, in vivo.
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Material and Methods
Chemicals, reagents, and antibodies. Rabbit polyclonal anti- CYP1A5
(Yip and Coulombe, 2006) and 3A37 (Chapter 3) sera were raised against the
peptide sequence “FLDFNKRFMKLLKTAVEE (amino acids 260-277)” and
“SQKSDSDGKNSHKA (amino acids 278-291),” respectively (Genemed
Synthesis, San Antonio, TX). These peptide sequences were selected by the
manufacturer while taking into consideration that they should be antigenic,
hydrophilic and readily accessible. Liver tissues were obtained from 1-day old
male white turkeys, generously provided by Dr. Lynn Bagley, Moroni Feed Co.
(Moroni, UT). All other chemicals were purchased from Sigma-Aldrich (St.
Louis, MO).
Microsomal metabolism and determination of AFB1 metabolites. Turkey
liver microsomes were prepared as previously described (Klein et al., 2002). The
exo-AFBO intermediate is unstable and has a very short half-life, so it was
determined indirectly as a stable, trapped AFBO-GSH conjugate using conditions
described previously (Yip and Coulombe, 2006). A reaction mixture consisting of
turkey liver microsomes (~400 μg), butylated hydroxyl anisole (BHA)-induced
mouse cytosol (~800 μg total protein) as a source of GST, 2mM NADPH, 5mM
GSH and 0.1-1000 μM AFB1 in spectral grade dimethyl sulfoxide (DMSO) was
made in epoxide trapping buffer (5 mM MgCl2, 25 mM KCl, 0.25 mM sucrose,
and 80 mM potassium phosphate, pH 7.6) to give a final volume of 250 μL. The
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reaction mixtures were incubated at 37ºC for 20 min with gentle shaking and
stopped by adding 250 μL of cold methanol spiked with 24 μM aflatoxin G1 as an
internal standard. The samples were kept overnight at -20 ºC to facilitate protein
precipitation and then centrifuged at 13000Xg for 10 min. The supernatants were
filtered through a 0.2 μm nylon membrane before 100 μL were injected into the
HPLC. Metabolites were separated on a Shimadzu LC system (Shimadzu,
Pleasanton, CA), equipped with a model LC-20AD pump, a model SPD-20AV
UV-vis detector, and an Econosphere C18 (150 mm X 4.6 mm) column (Alltech
Associates, Deerfield, IL) kept at 40ºC. The elution of the peaks was monitored
by UV absorbance (λ=254 nm). The mobile phases used in this assay were as
described previously (Klein et al., 2000). Metabolite formation was quantified
using curves between the peak areas in the chromatograms and the amounts of
metabolites injected, using authentic AFBO-GSH, AFM1 and AFQ1 standards.
Inhibition of microsomal CYP1A5 and 3A37 activities by anti-peptide
antibodies. Anti-CYP1A5 or 3A37 immune serum (10 μg/ml/μg microsomal
protein) or control preimmune serum ( 10 μg/ml/μg microsomal protein) were
pre-incubated with the TLMs for 10 min at 4 ºC before adding the other
components of the epoxide trapping assay.
Statistical analysis. Kinetic data were analyzed by SigmaPlot Enzyme
Kinetics Module software (Systat Software, Inc., San Jose, CA). Data for
CYP3A37 kinetics were analyzed by nonlinear regression using the Hill equation
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to calculate Vmax and Km [V= Vmax [S]n/ ([Km]n + [S]n)]. In this equation, n
represents the number of apparent binding sites. On the other hand, data for
CYP1A5 kinetics were fit using the Michaelis-Menton equation [V= Vmax [S]/ (Km
+ [S])].
Results
Metabolism of AFB1 by control TLMs. We used microsomes from the
commercial birds, as they are shown to be more susceptible than the wild
varieties (Quist et al., 2000). The differences may be due to the activity of GST, as
P450 mediated oxidation of AFB1 from different varieties (wild, heritage and
commercial) exhibited similar kinetics (data not shown). Oxidation of AFB1 to
different metabolites was studied over concentrations ranging from 0.1-1000 µM
using TLMs. Mean product formation rates from triplicate incubations were
determined simultaneously at each substrate concentration in control
(preimmune serum pretreated) microsomes and in the same microsomes
pretreated with anti-CYP1A5 or 3A37 immune serum, to eliminate the
contribution of CYP1A5 or 3A37 to product formation, respectively. AFB1 was
metabolized to three products in control microsomes: exo-AFBO, AFM1 and
AFQ1 in the ratio of (1: 0.53: 4.4). The V vs. S plot for the formation of these
metabolites is shown in Figure 4.1. The kinetic parameters are presented in Table
4.1.
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Metabolism of AFB1 by CYP3A37 (TLMs pretreated with anti-CYP1A5
immune serum). In general, the formation of exo-AFBO and AFM1 was inhibited
by pretreatment with anti-CYP1A5 immune serum, while AFQ1 formation was
resistant to inhibition. Like the E. coli expressed CYP3A37, the rates of exo-AFBO
and AFQ1 formation (in the ratio of 1: 6) followed sigmoidal Hill kinetics,
indicative of positive cooperativity (Figure 4.2 and 4.3). The Eadie-Hofstee plots
(Figure 4.2B for exo-AFBO, and 4.3B for AFQ1), indicated that 3A37 metabolism
of AFB1 followed sigmoidal kinetics with a second order relationship between
the substrate concentrations and product formation rates (Gallagher et al., 1996).
While the Km values (Table 4.1) were similar to those of E. coli expressed
CYP3A37 (exo-AFBO: 281 + 15 vs. 287 + 21 µM; AFQ1: 302 + 31 vs. 302 + 51 µM),
Vmax values (Table 4.1) were smaller (exo-AFBO: 0.41 + 0.01 vs. 1.45 + 0.07
nmol/min/nmol P450; AFQ1: 2.26 + 0.13 vs. 7.86 + 0.75 nmol/min/nmol P450)
(Chapter 3). The apparent number of binding sites (“n”) was consistent to those
in the E. coli expressed CYP3A37 (exo-AFBO: 1.9 + 0.14 vs. 1.9 ± 0.18; AFQ1: 1.6 +
0.15 vs. 1.6 ± 0.26) (Chapter 3). AFM1 formation was inhibited by anti-CYP1A5
immune serum at all AFB1 concentrations (data not shown).
Metabolism of AFB1 by CYP1A5 (TLMs pretreated with anti-CYP3A37
immune serum). The formation of exo-AFBO and AFQ1 were inhibited by
pretreatment with anti-CYP3A37 immune serum, while AFM1 formation was
relatively resistant to inhibition. Like the E. coli expressed turkey CYP1A5 (Yip
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and Coulombe, 2006), formation of exo-AFBO and AFM1 (in the ratio of 1: 4)
followed simple Michaelis-Menton kinetics (Figure 4.4 and 4.5). The kinetic
parameters listed in Table 4.1 show that Km values were similar to those of E. coli
expressed CYP1A5 (exo-AFBO: 69 + 26 vs. 65 + 12 µM; AFM1: 37 + 6 vs. 34 + 9
µM), while Vmax values were roughly 4-fold lower for AFM1 (0.28 + 0.01 vs. 0.91 +
0.07 nmol/min/nmol P450) and more than 8-fold lower for exo-AFBO (0.07 +
0.007 vs. 0.61 + 0.037 nmol/min/nmol P450) (Yip and Coulombe, 2006). AFQ1
formation was inhibited by anti-CYP1A5 immune serum at all concentrations of
substrate (data not shown).
Metabolism of AFB1 in TLMs pretreated with both anti-CYP1A5 and
3A37 immune serum. After inhibition of both the enzymes, no product
formation was observed.
Relative contribution of CYP1A5 and 3A37 in the epoxidation of AFB1 to
exo-AFBO. The inhibition of exo-AFBO formation in TLMs pretreated with antiCYP1A5 immune serum was most marked at low concentrations of AFB1, while
pretreatment with anti-CYP3A37 immune serum resulted in marked inhibition of
exo-AFBO at relatively high concentrations of AFB1 (Figure 4.6). At
submicromolar AFB1 concentrations (0.1 µM), CYP1A5 contributed about 98% to
the total exo-AFBO formation (Figure 4.6). At the same concentrations, CYP1A5
produced a higher ratio (50: 1) of activation to detoxification product (exo-AFBO:
AFM1) compared to CYP3A37 (exo-AFBO: AFQ1 = 0.17: 1) (Table 4.2).
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Discussion
Previous studies in our laboratory have established that CYP1A5 and
3A37, homologues to human CYP1A2 and 3A4, respectively, are the most
important P450 isoforms responsible for the biotransformation of AFB1 in turkey
liver (Klein et al., 2000; Yip and Coulombe, 2006; Chapter 3). Although both
CYP1A5 and 3A37 epoxidate AFB1, their relative importance is uncertain because
of several complicating factors: a) both enzymes produce activation (exo-AFBO)
and detoxification products (AFM1 and AFQ1 by 1A5 and 3A37, respectively), b)
the affinities of CYP1A5 and 3A37 toward AFB1 are substantially different (Yip
and Coulombe, 2006; Chapter 3), and c) AFB1 metabolism by these enzymes
conform to different kinetic models. The relative importance of human CYP1A2
and 3A4 with respect to AFB1 epoxidation have been the subject of conflicting
reports mostly due to similar complications (Ramsdell and Eaton, 1990; Ueng et
al., 1995; Gallagher et al., 1996; Kamdem et al., 2006). Indeed, there are striking
similarities between human and turkey 1A and 3A homologues with respect to
AFB1 metabolism in liver microsomal and heterologously-expressed systems
(Gallagher et al., 1994, 1996; Yip and Coulombe, 2006; Chapter 3).
In this study, we examined the kinetics of AFB1 oxidation by CYP1A5 and
3A37 in TLMs, using anti-CYP1A5 and 3A37 immune serum as tools for
sequentially isolating individual AFB1-metabolizing P450s for the purpose of
identifying the predominant enzyme with particular attention to
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environmentally-relevant or “real-world” concentrations seen in the livers of
AFB1-exposed animals.
When the contribution of CYP3A37 was eliminated by immunoinhibition,
TLMs oxidized AFB1 to just two products, exo-AFBO and AFM1, characterized by
hyperbolic Michaelis-Menton kinetics. Identical characteristics have been
observed in E. coli expressed CYP1A5 (Yip and Coulombe, 2006) and human
CYP1A2 (Gallagher et al., 1996). Conversely, when CYP1A5 was
immunoinhibited, TLMs produced exo-AFBO and AFQ1, best fitting sigmoidal
Hill kinetics in agreement with the previous reports for CYPs 3A4 and 3A37
(Gallagher et al., 1996; Chapter 3). Examination of the Hill equation parameters
suggested that, while the affinity of CYP3A37 for AFB1 is less than that of
CYP1A5, its maximal velocity is about 6-times greater.
The sigmoidal relationship observed between the substrate concentrations
and the rates of product formation, suggests that CYP3A37 interacts with AFB1 in
an allosteric manner, indicative of positive cooperativity. Similar sigmoidal
behavior for P450 3A in other species have been observed. Using 7-benzyloxy-4(trifluoromethyl)-coumarin (BFC) and nonylphenol as CYP3A substrates, both
homotropic and heterotropic cooperative interactions were described in fish
(Kullman et al., 2004). Furthermore, human CYP3A4-catalyzed, oxidation of AFB1
to AFBO and AFQ1, and formation of temazepam from diazepam showed
allosterism, with the data fitting well to sigmoidal Vmax model equivalent to the
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Hill equation (Andersson et al., 1994; Gallagher et al., 1996). In addition,
Gallagher et al (1996) observed sigmoidal kinetics for the formation of AFBO and
AFQ1 in human liver microsomes pretreated with furafylline, a mechanism based
inhibitor of CYP1A2. Several models have been proposed for the cooperativity
observed with CYP3A4 homologues, indicating the presence of a distinct
allosteric site, where binding of an effector or substrate molecule enhances
binding of substrate at the active site and involves a change in the conformation
of the active site (Ueng et al., 1997; Davydov and Halpert, 2008).
This atypical sigmoidal second-order kinetics associated with CYP3A37
and AFB1 implies that the rate of product formation falls off steeply at low
substrate concentrations (Gallagher et al., 1996). However, such is not the case
for CYP1A5 which follows first order hyperbolic Michaelis-Menton kinetics
(Gallagher et al., 1996). Our results clearly show that at lower AFB1
concentrations, such as at 0.1 µM, nearly all exo-AFBO is formed by CYP1A5
(Table 4.2). Residual AFB1 and stable detoxified metabolites in the livers of
chickens and other domesticated fowl were in the range of 0.15-7.83 and 1.5422.34 ppb, respectively, after an 8-day exposure to a diet containing containing 3
ppm AFB1 (Bintvihok et al., 2002). The higher range (~0.025-0.072 µM) of these in
vivo concentrations of AFB1 and of its metabolites is very close to 0.1 µM used in
our assays. While in vitro metabolic systems only provide an approximation of
the hepatic milieu in vivo, it seems reasonable to conclude that the formation of
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exo-AFBO, as well as the disposition of AFB1, at “real world” concentrations is
probably dominated by CYP1A5. The probability that the in vivo concentration
of AFB1 at the site of the P450 enzyme would actually exceed those used in in
vitro assay is very low; AFB1 needs to traverse the lipid membranes in order to
distribute and the total fraction of lipid at in vivo conditions would probably be
much higher than those of in vitro microsomal fraction (Gallagher et al., 1996).
Our data shows that, at 0.1 µM AFB1 concentrations, CYP1A5 produced a
much higher ratio (50: 1) of activation (exo-AFBO) to detoxification product
(AFM1), relative to CYP3A37. In addition, the ratio of activation: inactivation
products formed in TLMs also suggests relatively higher contribution of CYP1A5
to the AFB1 activation as compared to CYP3A37. Previous studies examining the
kinetics of AFB1 oxidation by E. coli expressed CYP1A5 and 3A37 in our
laboratory also indicates similar findings; CYP1A5 produced exo-AFBO and
AFM1 (AFB1 concentrations: 2 - 500 µM) in a ratio of 1: 2, while CYP3A37
produced exo-AFBO and AFQ1 (AFB1 concentrations: 0.1 - 1000 µM) in a ratio of
1: 6 (Yip and Coulombe, 2006; Chapter 3). The ratios of activation: inactivation
products catalyzed by CYP1A5 and 3A37 are likely to be an important factor in
the biological consequences of in vivo AFB1 exposure in turkeys. While CYP3A
activity is higher than that of 1A in the turkey liver (Guarisco et al., 2008), the
apparent low affinity of 3A37 at submicromolar liver AFB1 concentrations, makes
it highly unlikely that this enzyme would bioactivate AFB1 substantially in vivo.
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At 0.1 µM AFB1 concentrations, the ratio of the contributions of CYP1A5: 3A37 to
the formation of exo-AFBO is 98: 2.
Based on our results, inhibition of CYP1A5 may significantly alleviate the
symptoms of aflatoxicosis in poultry exposed to dietary AFB1. In fact, butylated
hydroxytoulene (BHT) added to turkey feed provided improvements in the
AFB1-associated symptoms in turkeys, in part, due to its inhibitory effect on
CYP1A5, exhibiting Michaelis-Menton competitive inhibition kinetics (Ki=0.81
µM) (Guarisco et al., 2008). Guarisco et al. (2008) also showed that BHT induces
CYP3A, which implies that this enzyme is probably not bioactivating AFB1 in
vivo; rather it may be contributing to the protective effects of BHT by possible
detoxification to AFQ1. In conclusion, our in vitro kinetic studies of AFB1
oxidation indicate that the dominant catalyst of AFB1 epoxidation at in vivo
dietary concentrations obtained in turkey liver is CYP1A5.
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Table 4.1. Kinetic constants of CYP1A5 and 3A37 catalyzed AFB1 (0.1-1000 μM)
metabolism in control, and immunoinhibited turkey liver microsomes.1,2,3
Metabolite Kinetic
constants

exo-AFBO

AFQ1

AFM1

Control

+ Anti-CYP1A5

+ Anti-CYP3A37

Vmax

0.47 + 0.03

0.41 + 0.01

0.07 + 0.007

Km

266 + 32

281 + 15

69 + 26

N

1.7 + 0.20

1.9 + 0.14

-

Vmax

2.07 + 0.13

2.26 + 0.13

ND4

Km

305 + 33

302 + 31

ND

N

1.7 + 0.18

1.6 + 0.15

ND

Vmax

0.25 + 0.009

ND

0.28 + 0.01

Km

41 + 6

ND

37 + 6

N

-

-

-

Microsomes were pretreated with anti-CYP1A5 or 3A37 immune serum (10
μg/ml/μg microsomal protein) for 10 min
2Vmax is expressed in nmol/min/nmol P450, Km in µM, N is the number of
apparent binding sites
3Data are mean + SE (n=3)
4ND: Not Detected
1
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Table 4.2. Relative contribution of CYP1A5 and 3A37 to the activation (exoAFBO) vs. inactivation (AFM1 and AFQ1) products formed in control and
immunoinhibited TLMs, at 0.1 µM AFB1, which are close to those potentially
encountered via real world dietary exposure.
Metabolite

Control
CYP1A5 (anti-CYP3A37 CYP3A37 (anti-CYP1A5
(Preimmune serum)
immune serum)
immune serum)

exo-AFBO1

18.8

18.5

0.19

AFM11

0.3

0.37

ND2

AFQ11

1.06

ND

1.23

1All

values are pmol/min/nmol P450.

2ND:

Not detected
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Figure 4.1. Kinetics of AFB1 metabolism in control TLMs (pretreated with
preimmune serum). Three metabolites were produced: exo-AFBO, AFM1 and
AFQ1, a metabolic profile indicative of functioning microsomal CYP1A5 and
3A37. Points are mean + SE (n = 3).
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Figure 4.2. The rates of exo-AFBO formation in TLMs pretreated with antiCYP1A5 immune serum (10 μg/ml/μg microsomal protein). The resultant exoAFBO formation showed sigmoidal Hill‟s kinetics, typical of CYP3A37. (A) V vs.
S plot of exo-AFBO formation. (B) Eadie- Hofstee plot of exo-AFBO formation.
Points are mean + SE (n = 3).
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Figure 4.3. The rates of AFQ1 formation in TLMs were not attenuated by
pretreatment with anti-CYP1A5 immune serum. AFQ1 formation which is
exclusively by CYP3A37 followed sigmoidal Hill‟s kinetics. (A) V vs. S plot of
AFQ1 formation. (B) Eadie- Hofstee plot of AFQ1 formation. Points are mean +
SE (n = 3).

106

Figure 4.4. The rates of exo-AFBO formation in TLMs pretreated with antiCYP3A37 immune serum (10 μg/ml/μg microsomal protein). After attenuation
of CYP3A37, exo-AFBO formation showed Michaelis-Menton kinetics, typical of
CYP1A5. The data were therefore were analyzed by fitting into MichaelisMenton equation. Points are mean + SE (n = 3).
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Figure 4.5. The rates of AFM1 formation in TLMs were not attenuated by
pretreatment with anti-CYP3A37 immune serum. AFM1 formation which is
exclusively by CYP1A5 followed simple Michaelis-Menton kinetics. Points are
mean + SE (n = 3).
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Figure 4.6. The relative contribution of CYP1A5 and 3A37 on AFB1 epoxidation
can be seen by the differential effects of anti-CYP1A5 and 3A37 immune serum
(10 μg/ml/μg microsomal protein) on the initial rates of exo-AFBO formation in
TLMs. Rates of exo-AFBO formation in the presence of antiserum were
calculated as percentage control (treatment with preimmune serum only). Each
bar is mean + SD. (n = 3).
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CHAPTER 5
CHEMOPREVENTION OF AFLATOXICOSIS BY PROBIOTC
LACTOBACILLUS IN TURKEYS
Abstract
Aflatoxin B1 (AFB1), a well-known human carcinogen, is a mycotoxin
produced as secondary metabolite by the fungi Aspergillus flavus, A. parasiticus,
and A. nominus. Poultry, specifically turkeys, are extremely sensitive to the toxic
effects of AFB1, which makes them an excellent model to study AFB1
chemopreventives. Probiotic bacteria are able to bind AFB1 and reduce its
bioavailability. Combinations of different probiotic bacteria are often used by the
food industry as biopreservatives, making them a suitable candidate to study for
chemopreventive actions. This study aims to investigate the protective action of
probiotic Lactobacillus: consisting of Lactobacillus rhamnosus strains GG and LC705, Propionibacterium freundenreichii sp shermani and Bifidobacterium sp (LGG),
on AFB1 toxicosis in turkeys. Day-old turkeys were chosen for this study and the
trial lasted for 21 days. After acclimatization for 10 days, birds were placed in
one of the four groups (n=10): LGG, LGG+AFB1, Control, and AFB1. Birds were
pretreated daily with 0.5 ml of either LGG (5 X 1010 cfu/0.5 ml PBS, prepared by
directly suspending lyophilized bacteria in PBS) (groups: LGG and LGG+AFB1)
or PBS (groups: Control and AFB1), by oral gavage for the first 10 days, before
starting AFB1 treatment at 1 ppm in the diet. Birds received LGG, PBS and AFB1
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for the rest of the period of the trial depending upon the group assignment. LGG
+ AFB1-treated group showed significantly higher body and liver weights than
those treated with AFB1-alone. Serum profile, histopathological and AFB1-lysine
adduct data supports the protective role of LGG, however the differences were
not statistically significant. In conclusion, our results indicate that LGG provides
protection against some of the deleterious effects of AFB1 and that this probiotic
may prove to be a viable chemopreventive for aflatoxicosis in turkeys.
Introduction
Aflatoxins, produced as secondary metabolites of the fungi Aspergillus
flavus, A. parasiticus, and A. nominus, are classified human carcinogens (Bondy
and Pestka, 2000). Of all aflatoxins, AFB1 is the most toxic, causing growth
impairment and immunosuppresion in a range of domesticated animals and
livestock (Richard et al., 1986; Coulombe, 1993). The toxicity of AFB1 is
dependent on the formation of exo-AFB1-8,9-epoxide (AFBO) by cytochromes
P450 (CYP for gene; P450 for protein), which is electrophilic, and binds to DNA,
RNA and other critical cellular nucleophiles to cause cellular toxicosis,
mutagenesis and carcinogenesis (Ball and Coulombe, 1991; Coulombe, 1993;
Gallagher et al., 1996; Guengerich et al., 1996). Glutathione-S-Transferases (GST)
are able to detoxify the AFBO, by conjugating it with endogenous glutathione.
This detoxification mechanism is critical in determining the susceptibility of a
species to AFB1 toxicosis (Coulombe, 1993). Poultry, specifically turkeys, are
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extremely sensitive to the toxic effects of AFB1 (Carnaghan et al., 1966; Arafa et
al., 1981; Giambrone et al., 1985; Huff et al., 1986; Kubena et al., 1995; Klein et al.,
2000). Sensitivity of turkeys to AFB1 was first demonstrated by their association
with the “Turkey X Disease” which caused widespread deaths of turkeys and
other poultry throughout Europe in the 1960s (Stevens et al., 1960). We
previously established that this extreme sensitivity of turkeys to AFB1 is in part,
due to an unfortunate combination of efficient epoxidation by P450s and
deficient detoxification by GSTs (Klein et al., 2000; Yip and Coulombe, 2006;
Chapter 2). Aflatoxin B1 in turkey feed results in poor performance, decreased
body and organ weights, immunosuppression, morbidity, and mortality (Kubena
et al., 1990, 1991; Coulombe, 1993). According to a report by Council for
Agricultural Science and Technology, losses due to aflatoxins to US poultry
industry exceeded $143 million annually (CAST, 1989). A recent study reported
annual crop losses of $932 million due to mycotoxin contamination and
additional losses of $466 million in efforts to prevent or reduce contamination
(CAST, 2003). Given that AFB1 contamination in feed is nearly universal, and
therefore practically unavoidable (Coulombe et al., 2005), chemoprevention
strategies aimed at reducing AFB1 toxicity in poultry and other animals have
been the subject of numerous studies (Klein et al., 2002b, 2003; Guarisco et al.,
2008a, 2008b). Indeed, because of their sensitivity, poultry have been used as
models for discovery of novel AFB1 chemopreventives. Our laboratory recently
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studied AFB1 chemoprevention by the antioxidant butylated hydroxytoluene
(BHT). The protective properties of BHT appeared to be due to an inhibitory
effect on the activity of P450 1A1 and 1A2, suggesting reduced bioactivation of
AFB1 to the AFBO (Klein et al., 2003). Further studies revealed that dietary BHT
reduced AFBO formation, as well as other CYP1A5-mediated activities (Guarisco
et al., 2008b). Furthermore, dietary BHT caused significant reductions in AFB1
bioavailability, AFB1–DNA adduct formation in the liver, and reduced AFB1
residues in tissues (Guarisco et al., 2008a).
Probiotic bacteria, such as Lactobacillus rhamnosus, bind to AFB1, and play
a protective role in humans (Wollowski et al., 2001). Because of its use in various
dairy products, including yogurt, L. rhamnosus is therefore considered a good
candidate for evaluating its AFB1 chemopreventive potential in turkeys.
Lactobacillus rhamnosus strains GG and LC-705 were found to be the most efficient
in binding a range of mycotoxins including aflatoxins (El-Nezami et al., 1998,
2002a, 2002b; Haskard et al., 2001; Peltonen et al., 2001). In addition, L. rhamnosus
reduced AFB1 transport, metabolism, and toxicity in Caco-2 cells (Gratz et al.,
2007). Furthermore, L. rhamnosus reduced the AFB1 bioavailability in rats, thereby
decreasing its toxicity (Gratz et al., 2006). Thus, there exists substantial evidence
of the protective role of probiotics in preventing aflatoxicosis. The present study
aims to evaluate the chemopreventive action of LGG on AFB1 toxicity in turkeys,
a species extremely susceptible to aflatoxicosis.

113
Material and Methods
Bacterial strains. A freeze-dried mixture of probiotics, “LGG” (Valio Ltd.,
Helsinki, Finland), consisting of Lactobacillus rhamnosus GG (2.3 X 1010 cfu/g),
Lactobacillus rhamnosus LC-705 (3.0 X 1010 cfu/g), Propionibacterium freundenreichii
sp shermani (3.5 X 1010 cfu/g), and Bifidobacterium sp (2.9 X 1010 cfu/g) was
generously provided by Dr. Hani El-Nezami, University of Kuopio (Kuopio,
Finland). Additionaly, this mixture contained 58% microcrystalline cellulose,
27% gelatin, and magnesium stearate. LGG was administered to turkeys by oral
gavage in final concentrations of 5 X 1010 CFU/0.5 ml phosphate buffered saline
(PBS), prepared by directly suspending lyophilized bacteria in PBS (Gratz et al.,
2006).
Animals and Treatment. Animals were cared for under institutional
approval in an AAALAC-accredited facility. The Utah State University Animal
Care and Use Committee approved all procedures involving animal care,
euthanasia and tissue collection. Turkeys and feed were generously provided by
Moroni Feed Co. (Ephraim, UT). One day-old male Nicholas strain turkeys were
used for this study because previous studies indicate that younger birds are
more susceptible to aflatoxicosis than older ones (Klein et al., 2002a). Birds were
maintained on a corn-based commercial starter diet for the duration of the trial,
which lasted 21 days. After acclimatization for 10 days, birds were randomly
placed in one of the four groups (n=10): LGG, LGG + AFB1, Control, and AFB1.
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For the first 10 days, birds placed in LGG and LGG + AFB1 groups received
pretreatment with 0.5 ml of LGG and those placed in Control and AFB1 groups
received pretreatment with PBS (0.5 ml), once daily, by oral gavage, after which
AFB1 treatment (for groups: LGG + AFB1 and AFB1) was started at 1 ppm in the
diet. Aflatoxin B1 and LGG or PBS treatment continued for the next 11 days.
Thereafter, animals were euthanized by CO2 asphyxiation. Blood was collected
by cardiac puncture in sterile, no-additive tubes (Becton Dickinson Vacutainer®,
Franklin Lakes, NJ) for serum and in heparinized tubes for plasma collection,
and livers were rapidly removed and frozen on dry ice. The plasma and serum
were removed within 1 h of blood collection. Livers were sectioned for
histological analysis as described below, prior to freezing. The collected serum,
plasma and tissues were stored at − 80 °C until analyzed. Small sections of
spleens were cut and stored in RNA later (Ambion Inc., Austin, TX) solution for
cytokine gene expression analysis. Turkeys were weighed on day 1, 8, 15, 19 and
before euthanasia on day 21 and livers were weighed when sampled on day 21st.
Histological analysis. Liver sections were fixed in neutral buffered 10%
formalin immediately upon removal. A section of each liver was embedded in
paraffin using a Model TP1050 Embedding Station (Leica Microsystems,
Deerfield, IL), thin sectioned (RM 2145 Microtome, Leica Microsystems), and
stained with hematoxylin and eosin (H&E) (Jung Autostainer XL, Leica
Microsystems). Tissues were then fixed to the slides for histological analysis.

115
Each slide was evaluated for hepatic necrosis and biliary hyperplasia. A
numerical score of 1 to 5 for the severity was assigned to each sample as follows
(Klein et al., 2002b): hepatocellular necrosis, based on percent of viewed cells
affected, 1 =< 5%, 2 = > 5 to 30%, 3 = > 30 to 60%, 4 = > 60 to 80%, or 5 = > 80%;
biliary hyperplasia, 1 = normal, 2 = mild proliferation without parenchymal
displacement, 3 = moderate proliferation with some mild parenchymal
displacement, 4 = moderate to severe proliferation with moderate parenchymal
displacement, or 5 = diffuse proliferation with severe parenchymal displacement.
Cytokine gene expression analysis. RNA was extracted from RNA later
stored spleens, using an RNeasy Mini Kit (Qiagen). cDNA was transcribed using
a high capacity cDNA Reverse Transcription Kit (Applied Biosystems).
Quantitative real-time PCR was performed on an Applied Biosystems 7500 Fast
machine using Fast SYBR Green (Applied Biosystems). The run conditions were
as follows: 20 seconds of initial denaturation at 95°C, 40 cycles of denaturation at
95°C at 3 seconds each, and 30 seconds of annealing and extension at 60°C.
Aflatoxin-lysine (AFB1-lys) adducts analysis. Samples were analyzed for
AFB1-lys by Liquid chromatography-Mass Spectrometry (LC/MS/MS) by a
modified method as described previously (McCoy et al., 2005). This method
involves digestion and isolation of AFB1 adducts, but only measures AFB1-lys.
AFB1-lys residues previously separated by LC were MS fragmented.
Quantification used authentic standards.
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Statistical analysis. Groups were compared, for differences, using
appropriate ANOVA models and post-hoc tests as described under results. A
level of p < 0.05 was chosen as statistically significant.
Results
Mean body weights for each treatment group over the course of the trial
are summarized in Figure 5.1. LGG exerted a strong protective effect against
primary endpoints of aflatoxicosis, like percent body weight gains, which were
analyzed by a two-way factorial ANOVA model with main factors treatment
(LGG treatment or not) and diet (AFB1 or not) using proc mixed in SAS (Cary,
NC). LGG-treated birds had significantly higher weight gains as compared to
those which did not receive this treatment, with an estimated difference of about
83 % (p-value < 0.0001). As anticipated, birds receiving non-AFB1 diets, had
significantly higher weight gains than those which received AFB1 in their diet,
with an estimated difference of about 52 % (p-value = 0.0005). Percent body
weight gain on day 21 relative to day 1 shows that, AFB1-alone group
experienced a significantly lower weight gain as compared to other groups
(Figure 5.2) (p-values adjusted for multiple comparison were all 0.0002 or less),
while the pairwise differences amongst groups LGG, LGG + AFB1 and Control
were not significant (smallest adjusted p-value for between-group comparison
was 0.10, for LGG vs. Control). While AFB1-alone group experienced about 350%
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body weight gain, LGG, LGG +AFB1 and Control groups experienced, on an
average over 440% (Figure 5.2).
Protective effects of LGG were also seen when liver weight was
considered. Summary of liver and body weights and liver: body weight ratios on
the day of sampling (day 21) are shown in Table 5.1. Similar to the ANOVA
model for percent body weight gain, an ANOVA model was fit to the liver
weight data. Model diagnostics identified the lowest liver weight in one of the
birds in the LGG +AFB1-group as an outlier, so that bird was dropped from the
liver weight analysis. From this model, birds receiving the non-AFB1 diet had
significantly higher liver weights than those with AFB1 in diet (estimated
difference 3.2g, p-value < 0.0001). There was no significant liver weight
difference due to LGG treatment. There was no significant difference between
the liver weights means amongst LGG, LGG + AFB1 and Control groups
(smallest adjusted p-value for between-group comparison is 0.15, for LGG +
AFB1 vs. Control), while even after adjusting for multiple comparisons, AFB1alone group liver weight was significantly lower than LGG (estimated difference
4.20g, p-value=0.0003), LGG + AFB1 (estimated difference 2.97g, p-value=0.02),
and Control (estimated difference 5.16g, p-value < 0.0001) groups. Groups fed
AFB1 diet had significantly lower liver : body weight ratios than those receiving
non-AFB1 diets.
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The principal target organ of AFB1 toxicosis is the liver. To assess the
degree of hepatic damage, serum profiles were analyzed (Figure 5.3). Serum data
were analyzed for within group differences using one-way ANOVA model with
a post-hoc Tukey test. Serum gamma-glutamyltransferase (GGT) was
significantly elevated in AFB1-treated groups as compared to the groups fed nonAFB1 diet. The mean level of GGT was slightly lower, but not significantly
different; in LGG + AFB1-group as compared to those of AFB1-alone group (12.8
+ 1.6 versus 12.6 + 5.7 U/L). Both total protein and albumin were significantly
lower in AFB1-treated groups as compared to the non-AFB1 groups. Serum
alkaline phosphatase, however, was significantly elevated in groups fed nonAFB1 diet than those in AFB1-treated animals. There was no statistically
significant trend associated with AST, ALT, and bilirubin values (data not
shown).
After the birds were sacrificed, their livers were grossly examined for
hepatic changes, such as hemorrhaging, tissue firmness and color changes.
Visual examination showed that livers from AFB1-alone groups were pale and
firm, whereas these changes were reduced in LGG + AFB1-treated group and
completely absent in groups fed non-AFB1 diet. Histology of liver sections
revealed hepatic necrosis and biliary hyperplasia in AFB1- treated birds (Table
5.2), which were absent in control birds. Hepatic necrosis was mildly reduced in
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turkeys treated with LGG + AFB1 as compared to AFB1-alone group, but the
differences were not statistically significant.
The relative gene expression of proinflammatory cytokines IL-8 and IL-1β,
and anti-inflammatory cytokines IL-10 and IL-6 was analyzed by real-time PCR,
using GAPDH as the endogenous control. AFB1-alone group showed
upregulation of IL-1β and IL-10, and downregulation of IL-8 and IL-6, as
compared to those of LGG + AFB1-group (Figure 5.4). Results were highly
variable and there was no statistically significant trend associated with any of the
cytokines.
Mean amounts of AFB1-lys adducts in the plasma were lower in
LGG+AFB1-treated group than those in AFB1-alone group, though the difference
was not statistically significant (1773 ± 215.9 versus 2169 ± 194.5 pg/mg) (Figure
5.5). These adducts were not detected in the birds fed non-AFB1 diet. Visual
inspection over the course of the trial indicated that birds which received LGG,
were in general more active.
Discussion
Previous results from our laboratory has established that the extreme
sensitivity of turkeys to AFB1 is due, in part, to efficient P450 mediated
bioactivation and deficient detoxification by GSTs (Klein et al., 2000; Yip and
Coulombe, 2006; Chapter 2). Given that AFB1 is an unavoidable contaminant of
poultry feed (Coulombe et al., 2005), chemopreventive measures aimed to reduce
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the toxicity of AFB1 have been a subject of intense research. Here, we report the
protective role of LGG against some end points of aflatoxicosis in turkeys.
Probiotics have been previously shown to bind AFB1 and subsequently reduce its
toxicity in-vivo in rats and in-vitro in cultured Caco-2 cells (Gratz et al., 2006,
2007). To our knowledge, this has not been reported for turkeys thus far.
The beneficial effects of orally administered LGG were observed in key
endpoints of aflatoxicosis. First, reduction in body weight gain due to AFB1
returned to control values by LGG treatment, which was presumably due to the
binding of AFB1 by LGG leading to its excretion (Gratz et al., 2006). Turkeys are
an agriculturally important production animal in the United States, thus weight
gain is of critical economic importance and must be taken into consideration in
the evaluation of any chemopreventive. Protective effects of LGG on AFB1induced weight loss were seen in rats (Gratz et al., 2006). Similar protective
binding of AFB1 by strains of Lactobacillus and Propionibacterium was seen in
chickens (El-Nezami et al., 2000).
Although AFB1 generally affects most systems, liver is the principal organ
of effect for AFB1 toxicosis. Aflatoxin B1 has been shown to reduce the relative
liver weights in turkeys (Klein et al., 2002b; Kubena et al., 1995). LGG provided
amelioration in the AFB1-associated reduction in liver weights in turkeys. Serum
enzyme and histopathological data showed protection, but the differences were
not significant. These findings are potentially suggestive of increased retention of
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aflatoxin by LGG in the gastrointestinal tract of turkeys, which may consequently
reduce the toxicity of a high AFB1 exposure.
Aflatoxins are immunosuppresive in poultry, in part, through their effects
on cytokines (Qureshi et al., 1998; Yarru et al., 2009). Our results indicate
downregulation of anti-inflammatory cytokine, IL-6, in AFB1-alone group, which
was consistent with earlier reports (Yarru et al., 2009). AFB1-induced alteration of
cytokine expression among species appears to be highly variable (Rossano et al.,
1999; Liu et al., 2002). Although the gene expression of cytokines was not
significantly altered due to LGG treatment, our results provide an additional
evidence for a species-dependent immune response to AFB1.
Treatment with LGG lowered, but did not alter the AFB1-lys adduct
amounts significantly. Similar findings were reported by Gratz et al. (2006),
suggesting a saturation of the hepatic metabolizing capacity within the dosing
regimen used.
Thus, LGG provided some evidence of its protective effects in AFB1associated toxicity in turkeys. Several strains of probiotic bacteria are known to
bind a range of mycotoxins including aflatoxins. Of these strains, Lactobacillus
rhamnosus strain GG and LC-705 appears to be most efficient in binding AFB1 to
the bacterial surface (El-Nezami et al., 1998, 2002a, 2002b; Haskard et al., 2001). In
conclusion, LGG provides protection against AFB1-induced reduction in body
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and liver weights in turkeys, however chronic studies are required to evaluate its
potential role as a possible chemopreventive against aflatoxicosis in turkeys.
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Table 5.1. The effect of orally administered LGG on liver, body, and liver to body
weight ratio in turkeys on the day (21st) of sampling1.
Treatment

Liver Weight2

Body Weight2

LGG

19.23 (1.91)a

854.11 (83.05)a,c

Liver/body weight
ratio2
0.03 (0.002)a

LGG+AFB1

18.00 (2.18)a

901.15 (94.97)a,c

0.02 (0.001)b

Control

20.19 (2.98)a

825.79 (129.44)b,c

0.03 (0.002)a

AFB1

15.03 (0.98)b

738.71 (60.55)b

0.02 (0.001)b

1Male

turkeys were placed in one of the four groups: LGG, LGG+AFB1, Control,
and AFB1. After 10 days of pretreatment with either LGG (groups: LGG and
LGG+AFB1) or PBS (groups: Control and AFB1), 1 ppm AFB1 was added to the
diets of two AFB1-treated groups. Birds received LGG, PBS and AFB1 for the next
11 days, depending upon the group assignment.
2Values

are mean (+ SD) n = at least 9. Different superscripts indicate significant
differences among groups (p < 0.05).
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Table 5.2. Histopathologic lesion severity scoring of turkeys in different groups1.
Treatment

Biliary Hyperplasia2

Hepatic Necrosis2

LGG

1.00 (0.00)a

1.10 (0.31)a

LGG+AFB1

3.33 (1.12)b

2.00 (0.50)b

Control

1.00 (0.00)a

1.00 (0.00)a

AFB1

3.09 (0.94)b

2.18 (0.40)b

1Male

turkeys were placed in one of the four groups: LGG, LGG+AFB1, Control,
and AFB1. After 10 days of pretreatment with either LGG (groups: LGG and
LGG+AFB1) or PBS (groups: Control and AFB1), 1 ppm AFB1 was added to the
diets of two AFB1-treated groups. Birds received LGG, PBS and AFB1 for the next
11 days, depending upon the group assignment.
2Values are mean (+ SD) n = atleast 9. Different superscripts indicate a significant
difference among groups (p < 0.05).
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Figure 5.1. The protective effect of orally administered LGG on AFB1-induced
declines in mean body weights in turkeys over the course of the study. On day 1,
LGG, LGG + AFB1 and Control groups had 10 birds each, while AFB1-alone
group had 11. One bird in LGG + AFB1 died on day 3rd after the start and no
other mortalities were seen during the course of the trial.
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Figure 5.2. The chemopreventive effect of orally administered LGG on AFB1induced reduction in percent body weight gain (on day 21 relative to day 1) in
turkeys. AFB1-alone group had significantly lower weight gain than rest of the
groups. Male turkeys were placed in one of the four groups: LGG, LGG+AFB1,
Control, and AFB1. After 10 days of pretreatment with either LGG (groups: LGG
and LGG+AFB1) or PBS (groups: Control and AFB1), 1 ppm AFB1 was added to
the diets of two AFB1-treated groups. Birds received LGG, PBS and AFB1 for the
next 11 days, depending upon the group assignment. Each box represents the
mean + SD (n = atleast 9). Different superscripts indicate significant difference
among groups (p<0.05) (n = at least 9).
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Figure 5.3. The effect of orally administered LGG on serum chemistries in
turkeys. Male turkeys were placed in one of the four groups: LGG, LGG+AFB1,
Control, and AFB1. After 10 days of pretreatment with either LGG (groups: LGG
and LGG+AFB1) or PBS (groups: Control and AFB1), 1 ppm AFB1 was added to
the diets of two AFB1-treated groups. Birds received LGG, PBS and AFB1 for the
next 11 days, depending upon the group assignment. (A) ALP, (B) GGT, (C)
Total protein, (D) Total albumin. Each bar represents the mean + SD (n = at least
9). Different superscripts indicate a significant difference among groups (p <
0.05).
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Figure 5.4. The effect of orally administered LGG on Relative Quantification of
cytokines as assessed by RT-PCR in turkeys. Male turkeys were placed in one of
the four groups: LGG, LGG+AFB1, Control, and AFB1. After 10 days of
pretreatment with either LGG (groups: LGG and LGG+AFB1) or PBS (groups:
Control and AFB1), 1 ppm AFB1 was added to the diets of two AFB1-treated
groups. Birds received LGG, PBS and AFB1 for the next 11 days, depending upon
the group assignment.
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Figure 5.5. The effect of orally administered LGG on AFB1-lys adducts in turkeys.
AFB1-lys adducts were detected in plasma of groups receiving AFB1 in diet and
were absent in those receiving AFB1-free diet. Male turkeys were placed in one of
the four groups: LGG, LGG+AFB1, Control, and AFB1. After 10 days of
pretreatment with either LGG (groups: LGG and LGG+AFB1) or PBS (groups:
Control and AFB1), 1 ppm AFB1 was added to the diets of two AFB1-treated
groups. Birds received LGG, PBS and AFB1 for the next 11 days, depending upon
the group assignment. Each bar represents the mean + SD (n = at least 9).
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CHAPTER 6
SUMMARY AND FUTURE WORK
Extreme sensitivity of turkeys to AFB1 is explained in part, by the
presence of efficient epoxidating P450 1A and 3A homologues. This research
project aimed to identify and characterize these P450s in turkeys. Further
research focused on determining the relative importance of P450 1A5 and 3A37
in AFB1 epoxidation and to elucidate the detailed metabolism of AFB1 in turkey
liver microsomes. In another task, the chemopreventive action of probiotic
bacteria, Lactobacillus, was studied on AFB1 toxicity in turkeys. Because of their
extreme sensitivity, turkeys make an excellent model to study AFB1
chemopreventives.
The results of this study identified a CYP3A4 homologue, CYP3A37, from
the turkey liver. The gene for this P450 was found to have an ORF of 1512 bp,
and the protein was predicted to be 504 amino acids with 97% identity to chicken
CYP3A37. Our results demonstrates the utility of deletion of hydrophobic Nterminal nucleotide sequences (5‟ – end) to enhance the expression of P450s in E.
coli. The N-terminal truncated CYP3A37 expressed in E. coli produced substantial
amounts of active P450 to support the catalytic activities. The sequence of
CYP3A37 was 66% identical to human CYP3A4 and the catalytic activities of the
E. coli expressed protein closely resembled that of its human counterpart. For
example, CYP3A37 biotransformed AFB1 to exo-AFBO and AFQ1 and possessed
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nifedipine oxidase activity, both of which were inhibited by CYP3A4 inhibitor
17α-ethynylestradiol. Like the human CYP3A4, the kinetics of the oxidation of
AFB1 to exo-AFBO and AFQ1 by CYP3A37 conformed to sigmoidal Hill kinetics,
suggesting that there be an allosteric interaction between AFB1 and CYP3A37,
indicative of positive cooperativity. Of particular importance was the metabolism
of AFB1 by the E. coli expressed protein of CYP3A37 to exo-AFBO. Exo-AFBO, a
highly reactive electrophilic intermediate, is responsible for the carcinogenic and
mutagenic effects of AFB1. Thus, we concluded that CYP3A37 along with
CYP1A5 plays an important role in the extreme sensitivity of turkeys to AFB1.
After the characterization of both CYP1A and 3A homologues from the
turkey liver, we attempted to determine their relative importance in AFB1
epoxidation, in turkey liver microsomes. The combined presence of CYP1A5 and
3A37 in turkey liver, both of which metabolized AFB1 to the toxic exo-AFBO and
to detoxification products AFM1 and AFQ1, respectively, complicated the kinetic
analysis of the oxidation of this mycotoxin in turkey liver microsomes. Although
both the enzymes are efficient epoxidators of AFB1, the observed kinetics of the
AFB1 oxidation for CYP1A5 differed from those of CYP3A37. While CYP1A5
showed hyperbolic Michaelis-Menton, CYP3A37 exhibited sigmoidal Hill‟s
kinetics, indicative of an allosteric interaction, for the formation of AFB1
oxidation products.
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Immunoinhibition studies, utilizing anti-peptide sera directed against
CYP1A5 and 3A37, revealed that CYP1A5 very likely is the dominant homologue
in the formation of exo-AFBO at real world in vivo concentrations of AFB1, in the
turkey liver. Microsomal metabolism studies, in the presence or absence of
antiserum, using AFB1 concentrations ranging over 0.1-1000 µM, showed that
CYP1A5 is the major contributor to the formation of exo-AFBO at relatively low
concentrations of AFB1, reflective of those potentially encountered through
dietary exposure. CYP3A37, however, efficiently activated higher AFB1
concentrations, not likely to be achievable in turkey liver in vivo. We also
concluded that CYP1A5 acts as the higher affinity and CYP3A37 as the lower
affinity enzyme for AFB1, as indicated by their Km values. In these experiments,
the kinetics of the formation of different products of AFB1 metabolism, in turkey
liver microsomes, pretreated with either anti-CYP1A5 or 3A37 immune serum
was consistent with those observed with the individual P450s expressed in E.
coli. These studied helped us in not only determining the relative importance of
CYP1A5 and 3A37, but also to confirm their metabolic specificity, in the
formation of the metabolites of AFB1.
Since AFB1 is ubiquitous in corn-based poultry feed, we evaluated the
chemopreventive potential of probiotic, LGG, on AFB1 toxicity in turkeys. LGG
binds to AFB1, thus reducing its bioavailability and toxicity. Turkeys fed LGG in
their diet showed improvements in some key endpoints of aflatoxicosis. Birds
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which received LGG + AFB1 had significantly higher body and liver weights
than those of AFB1-alone. Serum profile, histopathological analysis and AFB1adduct analysis showed trends toward protective effects of LGG, but the
differences were not statistically significant. In conclusion, LGG offers some
protection against aflatoxicosis, thus validating its use as a possible
chemopreventive; however, chronic studies are required to confirm its use as a
dietary additive.
The results of this dissertation have provided insight into the role of P450s
in the extreme sensitivity of turkeys to AFB1. Commercial turkeys possess P450s
with high AFB1 epoxidation potential, which is associated with their sensitivity
to this mycotoxin. Our studies have helped unravel the relative importance of
CYP1A5 and 3A37, which will contribute toward the development of strategies
to protect poultry against the deleterious effects of AFB1. Because CYP1A5 is
likely the predominating isoform bioactivating AFB1 at in vivo dietary
concentrations, further research investigating the chemopreventives which could
inhbit CYP1A5, therefore merits study. Another direction may include
development of CYP1A5 gene knock-out models for poultry and studying their
susceptibility to AFB1. Based on the results of our studies, inhibition of CYP1A5
may provide significant improvements in AFB1-associated toxicity in turkeys. In
fact, the dietary antioxidant BHT was found to have protective effects on AFB1
toxicity, in part, because of its inhibitory effect on CYP1A5.
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Several evidences point towards the presence of P450s capable of
metabolizing xenobiotics in the intestines in other species; although in very small
quantities as compared to liver. Therefore, future work may include
examination of those P450 isoforms in the intestines from turkeys, which may
play a role in AFB1 epoxidation, before it reaches the liver.
Our laboratory has established that the extreme sensitivity of turkeys to
AFB1 is due, in part, to an unfortunate combination of efficient P450 mediated
epoxidation and deficient detoxification by GSTs. Commercial turkeys lack
isoforms of GSTs capable of conjugating the exo-AFBO. Future work, which is
currently on going in our laboratory, includes examination of the GSTs in wild
turkeys. Although direct comparisons have not been made, wild turkeys appear
to be relatively resistant to AFB1 as compared to their commercial counterparts.
The protective traits might have been lost in commercial turkeys, due to the
intense pressure of selective breeding. By identifying the relevant genetic
markers for the AF resistance, the protective traits in the commercial varieties,
may well be restored.
Additional work may be done to study other metabolic detoxification
enzymes, for example, epoxide hydrolase (EH). This enzyme acts on exo-AFBO
and converts it into a dihydrodiol derivative, which is hydrophilic and thus
could be excreted from the body. Single nucleotide polymorphisms in the
microsomal EH have been associated with the risk of development of
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hepatocellular carcinomas in humans; especially in regions where AFB1
contaminated foods constitute a staple diet.
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